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A B S T R A C T
Background
Pyrethroid long-lasting insecticidal nets (LLINs) have been important in the large reductions in malaria cases in Africa, but insecticide
resistance in Anopheles mosquitoes threatens their impact.  Insecticide synergists may help control insecticide-resistant populations.
Piperonyl butoxide (PBO) is such a synergist; it has been incorporated into pyrethroid-LLINs to form pyrethroid-PBO nets, which are
currently produced by five LLIN manufacturers and, following a recommendation from the World Health Organization (WHO) in 2017, are
being included in distribution campaigns. This review examines epidemiological and entomological evidence on the addition of PBO to
pyrethroid nets on their eCicacy.
Objectives
To compare eCects of pyrethroid-PBO nets currently in commercial development or on the market with eCects of their non-PBO equivalent
in relation to:
1. malaria parasite infection (prevalence or incidence); and
2. entomological outcomes.
Search methods
We searched the Cochrane Infectious Diseases Group (CIDG) Specialized Register, CENTRAL, MEDLINE, Embase, Web of Science, CAB
Abstracts, and two clinical trial registers (ClinicalTrials.gov and WHO International Clinical Trials Registry Platform) up to 25 September
2020. We contacted organizations for unpublished data. We checked the reference lists of trials identified by these methods.
Selection criteria
We included experimental hut trials, village trials, and randomized controlled trials (RCTs) with mosquitoes from the Anopheles gambiae
complex or the Anopheles funestus group.
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Data collection and analysis
Two review authors assessed each trial for eligibility, extracted data, and determined the risk of bias for included trials. We resolved
disagreements through discussion with a third review author. We analysed data using Review Manager 5 and assessed the certainty of
evidence using the GRADE approach.
Main results
Sixteen trials met the inclusion criteria: 10 experimental hut trials, four village trials, and two cluster-RCTs (cRCTs). Three trials are awaiting
classification, and four trials are ongoing.
Two cRCTs examined the eCects of pyrethroid-PBO nets on parasite prevalence in people living in areas with highly pyrethroid-resistant
mosquitoes (< 30% mosquito mortality in discriminating dose assays). At 21 to 25 months post intervention, parasite prevalence was
lower in the intervention arm (odds ratio (OR) 0.79, 95% confidence interval (CI) 0.67 to 0.95; 2 trials, 2 comparisons; moderate-certainty
evidence).
In highly pyrethroid-resistant areas, unwashed pyrethroid-PBO nets led to higher mosquito mortality compared to unwashed standard-
LLINs (risk ratio (RR) 1.84, 95% CI 1.60 to 2.11; 14,620 mosquitoes, 5 trials, 9 comparisons; high-certainty evidence) and lower blood feeding
success (RR 0.60, 95% CI 0.50 to 0.71; 14,000 mosquitoes, 4 trials, 8 comparisons; high-certainty evidence). However, in comparisons of
washed pyrethroid-PBO nets to washed LLINs, we do not know if PBO nets had a greater eCect on mosquito mortality (RR 1.20, 95% CI 0.88
to 1.63; 10,268 mosquitoes, 4 trials, 5 comparisons; very low-certainty evidence), although the washed pyrethroid-PBO nets did decrease
blood-feeding success compared to standard-LLINs (RR 0.81, 95% CI 0.72 to 0.92; 9674 mosquitoes, 3 trials, 4 comparisons; high-certainty
evidence).
In areas where pyrethroid resistance is moderate (31% to 60% mosquito mortality), mosquito mortality was higher with unwashed
pyrethroid-PBO nets compared to unwashed standard-LLINs (RR 1.68, 95% CI 1.33 to 2.11; 751 mosquitoes, 2 trials, 3 comparisons;
moderate-certainty evidence), but there was little to no diCerence in eCects on blood-feeding success (RR 0.90, 95% CI 0.72 to 1.11;
652 mosquitoes, 2 trials, 3 comparisons; moderate-certainty evidence). For washed pyrethroid-PBO nets compared to washed standard-
LLINs, we found little to no evidence for higher mosquito mortality or reduced blood feeding (mortality: RR 1.07, 95% CI 0.74 to 1.54; 329
mosquitoes, 1 trial, 1 comparison, low-certainty evidence; blood feeding success: RR 0.91, 95% CI 0.74 to 1.13; 329 mosquitoes, 1 trial, 1
comparison; low-certainty evidence).
In areas where pyrethroid resistance is low (61% to 90% mosquito mortality), studies reported little to no diCerence in the eCects
of unwashed pyrethroid-PBO nets compared to unwashed standard-LLINs on mosquito mortality (RR 1.25, 95% CI 0.99 to 1.57; 948
mosquitoes, 2 trials, 3 comparisons; moderate-certainty evidence), and we do not know if there was any eCect on blood-feeding success
(RR 0.75, 95% CI 0.27 to 2.11; 948 mosquitoes, 2 trials, 3 comparisons; very low-certainty evidence). For washed pyrethroid-PBO nets
compared to washed standard-LLINs, we do not know if there was any diCerence in mosquito mortality (RR 1.39, 95% CI 0.95 to 2.04; 1022
mosquitoes, 2 trials, 3 comparisons; very low-certainty evidence) or on blood feeding (RR 1.07, 95% CI 0.49 to 2.33; 1022 mosquitoes, 2
trials, 3 comparisons; low-certainty evidence).
In areas where mosquito populations are susceptible to insecticides (> 90% mosquito mortality), there may be little to no diCerence in the
eCects of unwashed pyrethroid-PBO nets compared to unwashed standard-LLINs on mosquito mortality (RR 1.20, 95% CI 0.64 to 2.26; 2791
mosquitoes, 2 trials, 2 comparisons; low-certainty evidence). This is similar for washed nets (RR 1.07, 95% CI 0.92 to 1.25; 2644 mosquitoes,
2 trials, 2 comparisons; low-certainty evidence). We do not know if unwashed pyrethroid-PBO nets had any eCect on the blood-feeding
success of susceptible mosquitoes (RR 0.52, 95% CI 0.12 to 2.22; 2791 mosquitoes, 2 trials, 2 comparisons; very low-certainty evidence).
The same applies to washed nets (RR 1.25, 95% CI 0.82 to 1.91; 2644 mosquitoes, 2 trials, 2 comparisons; low-certainty evidence).
In village trials comparing pyrethroid-PBO nets to LLINs, there was no diCerence in sporozoite rate (4 trials, 5 comparisons) nor in mosquito
parity (3 trials, 4 comparisons).
Authors' conclusions
In areas of high insecticide resistance, pyrethroid-PBO nets have greater entomological and epidemiological eCicacy compared to standard
LLINs, with sustained reduction in parasite prevalence, higher mosquito mortality and reduction in mosquito blood feeding rates 21 to
25 months post intervention. Questions remain about the durability of PBO on nets, as the impact of pyrethroid-PBO nets on mosquito
mortality was not sustained over 20 washes in experimental hut trials, and epidemiological data on pyrethroid-PBO nets for the full
intended three-year life span of the nets is not available. Little evidence is available to support greater entomological eCicacy of pyrethroid-
PBO nets in areas where mosquitoes show lower levels of resistance to pyrethroids.
P L A I N   L A N G U A G E   S U M M A R Y
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Bed nets treated with pyrethroid insecticides are an eCective way to reduce malaria transmission and have been deployed across Africa.
However, mosquitoes that spread malaria are now developing resistance to this type of insecticide. One way to overcome this resistance
is to add another chemical - piperonyl butoxide (PBO) - to the net. PBO is not an insecticide, but it blocks the substance (an enzyme) inside
the mosquito that stops pyrethroids from working.
What is the aim of this review?
The aim of this Cochrane Review was to find out if pyrethroid-PBO nets provide additional protection against malaria when compared to
standard pyrethroid-only nets.
Key messages
Pyrethroid-PBO nets were more eCective than standard pyrethroid-only nets in killing mosquitoes and preventing blood feeding in areas
where mosquito populations are very resistant to pyrethroid insecticides (high-certainty evidence). Pyrethroid-PBO nets reduced the
number of malaria infections in areas of high pyrethroid resistance (moderate-certainty evidence), although further studies are needed to
measure clinical outcomes for the full lifetime of the net.
What was studied in the review?
We included 16 trials conducted between 2010 and 2020 that compared standard pyrethroid nets to pyrethroid-PBO nets. These consisted
of 10 experimental hut trials that measured the impact of pyrethroid-PBO nets on a wild population of mosquitoes, four village trials,
and two cRCTs. The two cRCTs measured the impact of pyrethroid-PBO nets on malaria infection in humans; all other studies recorded
their impact on mosquito populations. We analysed hut and village studies to determine whether pyrethroid-PBO nets were better for
killing mosquitoes and preventing them from blood feeding. For both cRCT trials, we examined whether pyrethroid-PBO nets reduced the
number of malaria infections. As the benefit of adding PBO to nets is likely to depend on the level of pyrethroid resistance in the mosquito
population, we performed separate analyses for studies conducted in areas of high, medium, and low levels of pyrethroid resistance.
What are the main results of the review?
When mosquitoes show high levels of resistance to pyrethroids, pyrethroid-PBO nets perform better than standard pyrethroid-only nets
for killing mosquitoes and preventing them from blood feeding. As expected, this eCect is not seen in areas where mosquitoes show low
or no resistance to pyrethroid-only insecticides. Two trials looked at the impact of using pyrethroid-PBO nets on the number of people
infected with the malaria parasite. These trials, involving 10,603 participants in total and conducted in an area where mosquitoes are very
resistant to pyrethroids, found that fewer people were infected with malaria when the population used pyrethroid-PBO nets than when
standard pyrethroid-only nets were used.
How up-to-date is this review?
We searched for all studies and trials that had been published up to 25 September 2020.
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S U M M A R Y   O F   F I N D I N G S
 
Summary of findings 1.   Summary of findings table 1
Pyrethroid-piperonyl butoxide (PBO) nets compared to long-lasting insecticidal nets (LLINs) for malaria control when insecticide resistance is high
Patient or population: Anopheles gambiae complex or Anopheles funestus group






















254 per 1000a 201 per 1000
(174 to 233)a
OR 0.74 (0.62 to
0.89)
11,582 people (2 trials,





Pyrethroid-PBO nets at 4- to 6-month follow-up







180 per 1000a 136 per 1000
(118 to 159)a
OR 0.72 (0.61 to
0.86)
11,370 people (2 trials,







Pyrethroid-PBO nets at 9- to 12-month follow-up







248 per 1000a 2258 per 1000
(196 to 255)a
OR 0.88 (0.74 to
1.04)
10,603 people (2 trials,







Pyrethroid-PBO nets at 16- to 18-month fol-







350 per 1000a 298 per 1000
(265 to 338)a
OR 0.79 (0.67 to
0.95)
10,603 people (2 trials,







Pyrethroid-PBO nets at 21- to 25-month fol-










































































































































































































Mosquito mortality is higher with unwashed
pyrethroid-PBO nets compared to standard un-

















We do not know whether pyrethroid-PBO nets
have an effect on mosquito mortality in areas of














Mosquito blood-feeding success is decreased
with unwashed pyrethroid-PBO nets compared














Mosquito blood-feeding success is decreased
with washed pyrethroid-PBO nets compared to
standard washed LLINs in areas of high insecti-
cide resistance
*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; LLINs: long-lasting insecticidal nets; OR: odds ratio; PBO: pyrethroid-piperonyl butoxide; RR: risk ratio.
GRADE Working Group grades of evidence.
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
aOriginal numbers were used in this table; however in pooled analysis, events and total numbers were generated from cluster-adjusted results, which use the eCective sample
size. Note that cluster adjustments do not change the point estimate of the eCect size - just the standard error.
bDowngraded by one for inconsistency.
cNot downgraded for imprecision: both best- and worst-case scenarios in this situation are important eCects.
dDowngraded by one for imprecision due to wide CIs.
eDowngraded by two for inconsistency due to unexplained qualitative heterogeneity.
 
 
Summary of findings 2.   Summary of findings table 2





























































































































































































Patient or population: Anopheles gambiae complex or Anopheles funestus group

































Mosquito mortality is probably higher with unwashed
pyrethroid-PBO nets compared to standard unwashed
















There may be little to no difference in the effect of
washed pyrethroid-PBO nets on mosquito mortality
compared to standard washed LLINs (washed) in areas















There is probably little to no difference in the effect of
pyrethroid-PBO nets (unwashed) on mosquito blood-

















There may be little to no difference in the effect of
washed pyrethroid-PBO nets on mosquito blood-feed-
ing success compared to standard washed LLINs in ar-
eas of moderate insecticide resistance
*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; LLIN: long-lasting insecticidal net; PBO: pyrethroid-piperonyl butoxide; RR: risk ratio.
GRADE Working Group grades of evidence.
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.





























































































































































































Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
aOriginal numbers are used in this table; however for the pooled analysis, we generated events and total numbers from cluster-adjusted results, which used the eCective sample
size. Note that cluster adjustments do not change the point estimate of the eCect size, just the standard error.
bDowngraded by one for imprecision due to wide CIs.
cNot downgraded for inconsistency, as only one trial measured this outcome in this setting.
dDowngraded by one for indirectness: the outcome is highly context-specific, and only one trial is included.
 
 
Summary of findings 3.   Summary of findings table 3
Pyrethroid-piperonyl butoxide (PBO) nets compared to long-lasting insecticidal nets (LLINs) for malaria control when insecticide resistance is low
Patient or population: Anopheles gambiae complex or Anopheles funestus group
































There is probably little to no difference in the effect
of unwashed pyrethroid-PBO nets on mosquito mor-
tality compared to standard unwashed LLINs in ar-















We do not know if pyrethroid-PBO nets have an ef-
fect on mosquito mortality in areas of low insecti-















We do not know if unwashed pyrethroid-PBO nets
have an effect on mosquito blood-feeding success in













Mosquito blood-feeding success may decrease with
washed pyrethroid-PBO nets compared to standard































































































































































































*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; LLIN: long-lasting insecticidal net; PBO: pyrethroid-piperonyl butoxide; RR: risk ratio.
GRADE Working Group grades of evidence.
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
aOriginal numbers are used in this table; however for the pooled analysis, events and total numbers were generated from cluster-adjusted results, which use the eCective sample
size. Note that cluster adjustments do not change the point estimate of the eCect size, just the standard error.
bDowngraded by one for imprecision due to wide CIs.
cDowngraded by one for inconsistency due to unexplained heterogeneity.
dDowngraded by two for imprecision due to extremely wide CIs.
 
 
Summary of findings 4.   Summary of findings table 4
Pyrethroid-piperonyl butoxide (PBO) nets compared to long-lasting insecticidal nets (LLINs) for malaria control when mosquitoes are susceptible
Patient or population: Anopheles gambiae complex or Anopheles funestus group

































There may be little to no difference in the effect of un-
washed pyrethroid-PBO nets on mosquito mortality












































































































































































































There may be little to no difference in the effect of
washed pyrethroid-PBO nets on mosquito mortality

















We do not know if unwashed pyrethroid-PBO nets
have an effect on mosquito blood-feeding success in
















We do not know if washed pyrethroid-PBO nets have
an effect on mosquito blood-feeding success in areas
of no insecticide resistance
*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; LLINs: long-lasting insecticidal nets; PBO: pyrethroid-piperonyl butoxide; RR: risk ratio.
GRADE Working Group grades of evidence.
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
aOriginal numbers are used in this table; however for the pooled analysis, events and total numbers were generated from cluster-adjusted results, which use the eCective sample
size. Note that cluster adjustments do not change the point estimate of the eCect size, just the standard error.
bDowngraded by two for imprecision due to extremely wide CIs.
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B A C K G R O U N D
Description of the condition
Substantial progress has been made in reducing the burden of
malaria in the 21st century. It is estimated that the clinical incidence
of Plasmodium falciparum malaria in Africa dropped by 40%
between 2000 and 2015, equating to prevention of 663 million
cases (Bhatt 2015; WHO-GMP 2015). However progress has stalled
in recent years (WHO 2019a). Targeting the mosquito vector has
proved to be the most eCective method of malaria prevention
in Africa, with over two-thirds of malaria cases averted in the
first 15 years of this century attributed to scale-up in the use of
long-lasting insecticidal nets (LLINs) (Bhatt 2015). This method of
malaria prevention is particularly eCective in Africa, where the
major malaria vectors Anopheles gambiae and Anopheles funestus
are largely endophagic (feed indoors) and endophilic (rest indoors
aQer blood feeding).
Currently all LLINs contain pyrethroids; pyrethroids have the
required dual properties of low mammalian toxicity and rapid
insecticidal activity (Zaim 2000), and their repellent or contact
irritant eCects may enhance the personal protection of LLINs.
Unfortunately, resistance to pyrethroids is now widespread
in African malaria vectors (Ranson 2016). This may be the
result of mutations in target-site proteins (target-site resistance)
(Ranson 2011; Ridl 2008), which result in reduced sensitivity to
the insecticide or increased activity of detoxification enzymes
(metabolic resistance) (Mitchell 2012; Stevenson 2011), or other
as yet poorly described resistance mechanisms, or a combination
of all or some of these factors. The evolution of insecticide
resistance and its continuing spread threaten the operational
success of malaria vector control interventions. The current impact
of this resistance on malaria transmission is largely unquantified
and varies depending on level of resistance, malaria endemicity,
and proportion of the human population using LLINs (Churcher
2016). A multi-country trial found no evidence that pyrethroid
resistance reduced the personal protection provided by the use
of LLINs (Kleinschmidt 2018). However, it is generally accepted
that resistance will eventually erode the eCicacy of pyrethroid-
only LLINs, and that innovation in the LLIN market is essential to
maintain the eCicacy of this preventative measure (MPAC 2016).
Description of the intervention
One way of controlling insecticide-resistant mosquito populations
is through the use of insecticide synergists. Synergists are generally
non-toxic and act by enhancing the potency of insecticides.
Piperonyl butoxide (PBO) is a synergist that inhibits specific
metabolic enzymes within mosquitoes and has been incorporated
into pyrethroid-treated LLINs to form PBO-combination nets
(hereaQer referred to as pyrethroid-PBO nets). Insecticide-synergist
combination nets represent a new product class with the capacity
to aCect insecticide-resistant populations. In 2017, the World
Health Organization (WHO) gave pyrethroid-PBO nets an interim
endorsement as a new vector control class and recommended that
countries consider deploying these nets in areas where pyrethroid
resistance has been confirmed among main malaria vectors (WHO-
GMP 2017a).
Currently six pyrethroid-PBO nets are in production: Olyset® Plus;
PermaNet® 3.0; Veeralin® LN; Tsara Plus (previously DawaPlus 3.0);
Tsara Boost (previously DawaPlus 4.0); and DuraNet Plus. Olyset
Plus, which is manufactured by Sumitomo Chemical Company Ltd.,
is a polyethylene net treated with permethrin (20 g/kg ± 25%)
and PBO (10 g/kg ± 25%) across the whole net (Sumitomo 2013).
PermaNet 3.0, which is manufactured by Vestergaard Frandsen,
is a mixed polyester (sides) polyethylene (roof) net treated with
deltamethrin and PBO; PBO is found only on the roof of the net
(25 g/kg ± 25%), and the concentration of deltamethrin varies
depending on location (roof: 4.0 g/kg ± 25%) and yarn type (sides:
75-denier (thickness) yarn with 70-cm lower border 2.8 g/kg ± 25%,
100-denier yarn without border 2.1 g/kg ± 25%; Vestergaard 2015).
Veeralin LN, manufactured by Vector Control Innovations Private
Ltd., is a polyethylene net treated with alpha-cypermethrin (6.0 g/
kg) and PBO (2.2 g/kg) across the whole net (WHOPES 2016). Tsara
Plus and Tsara Boost are manufactured by NRS Moon Netting FZE.
Tsara Plus is treated with deltamethrin (3 g/kg) and PBO (11 g/
kg) on the roof, and with deltamethrin only (2.5 g/kg) on its sides.
Tsara Boost is treated with deltamethrin (120 mg/m2) and PBO (440
mg/m2) on all panels. DuraNet Plus, manufactured by Shobikaa
Impex Private Limited, is a polyethylene net treated with alpha-
cypermethrin (6.0 g/kg) and PBO (2.2 g/kg) across the whole net.
How the intervention might work
PBO inhibits metabolic enzyme families, in particular the
cytochrome P450 enzymes that detoxify or sequester pyrethroids.
Increased production of P450s is thought to be the most potent
mechanism of pyrethroid resistance in malaria vectors, and
pre-exposure to PBO has been shown to restore susceptibility
to pyrethroids in laboratory bioassays on multiple pyrethroid-
resistant vector populations (Churcher 2016).
Widespread use of conventional LLINs provides both personal and
community protection from malaria (Bhatt 2015; Lengeler 2004).
In areas where mosquito populations are resistant to pyrethroids,
experimental hut trials (as described in the Types of studies section)
have shown that mosquito mortality rates and protection from
blood feeding are substantially reduced when conventional LLINs
are used (Abílio 2015; Awolola 2014; Bobanga 2013; N'Guessan
2007; Riveron 2015; Yewhalaw 2012). The addition of PBO to
pyrethroids in LLINs can restore the killing eCects of LLINs in areas
where this has been eroded by insecticide resistance. LLINs that
contain PBO have been evaluated in multiple experimental hut
trials across Africa (Adeogun 2012; Bayili 2017; Corbel 2010; Koudou
2011; Menze 2020; Moore 2016; N'Guessan 2010; Oumbouke 2019;
Pennetier 2013; Toé 2018; Tungu 2010). In most settings, pyrethroid-
PBO nets resulted in higher rates of mosquito mortality and greater
blood-feeding inhibition than conventional LLINs, although the
magnitude of this eCect was variable. Village trials have measured
the impact on sporozoite infection rates in mosquitoes with mixed
results (Awolola 2014; Cisse 2017; Mzilahowa 2014; Stiles-Ocran
2013). Recently, two separate cluster-randomized trials (cRCTs) in
Tanzania and Uganda demonstrated that use of pyrethroid-PBO
nets can reduce parasite prevalence in children (ProtopopoC 2018;
Staedke 2020).
Why it is important to do this review
All LLINs approved by the WHO Prequalification Team (formerly the
WHO Pesticide Evaluation Scheme (WHOPES)) contain pyrethroids.
Six bed nets that contain PBO have received WHO pre-qualification
and have been recognized as a new product class by WHO (WHO-
GMP 2017a). As pyrethroid-PBO nets are generally more expensive
than conventional LLINs, it is important to determine if they are
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superior to conventional LLINs, and under what circumstances,
to enable cost-eCectiveness trials to be performed to inform
procurement decisions.
An Expert Review Group (ERG) commissioned by the WHO has
recommended pyrethroid-PBO nets be considered for use in areas
where the major malaria vectors are resistant to pyrethroids
(WHO-GMP 2017a). This guidance has been adopted by some net
providers, for example, the President's Malaria Initiative (PMI)
(PMI 2018). The WHO recommendation was largely based on a
single randomized controlled trial (RCT) of one pyrethroid-PBO net
type conducted in Tanzania (ProtopopoC 2018), but it was also
supported by a meta-analysis of performance of pyrethroid-PBO
nets in experimental hut trials, which was used to parameterize a
malaria transmission model to predict the public health benefit of
pyrethroid-PBO nets (Churcher 2016). The WHO recommendation
is that countries should consider deployment of this new product
class in areas with intermediate levels of pyrethroid resistance,
but it calls for further evidence, including data from a second
clinical trial (WHO 2019b). Results of a second RCT evaluating the
epidemiological impact of pyrethroid-PBO nets in Uganda were
published in 2020, and this review has been updated to include
these data (Staedke 2020).
In an attempt to assess evidence of eCectiveness of pyrethroid-
PBO nets against African malaria vectors in areas with diCering
levels of insecticide resistance, we have conducted a systematic
review of all relevant trials and examined both epidemiological
and entomological endpoints. We appreciate that evaluation of
PBO will depend on trials in which the background insecticide and
dose are the same in both intervention and control groups; we are
aware that most trials have evaluated pyrethroid-PBO nets against
pyrethroid-only LLINs with diCerent background insecticides and
doses, which confounds the eCects.
O B J E C T I V E S
To compare eCects of pyrethroid-PBO nets currently in commercial
development or on the market with eCects of their non-PBO
equivalent in relation to:
1. malaria parasite infection (prevalence or incidence); and
2. entomological outcomes
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included:
1. randomized trials that measured epidemiological outcomes,
entomological outcomes, or both; and
2. experimental hut trials.
See Table 1 for detailed WHOPES definitions.
Types of participants
Mosquitoes
Anopheles gambiae complex or Anopheles funestus group. Included
trials had to test a minimum of 50 mosquitoes per trial arm. We
examined the insecticide resistance level (measured by phenotypic
resistance) during data analysis.
Humans
Adults and children living in malaria-endemic areas.
Types of interventions
Intervention
Bed nets treated with both PBO and a pyrethroid insecticide. Nets
must have received a minimum of interim-WHO approval (Table 2),
and LLINs had to be treated with a WHO-recommended dose of
pyrethroid (Table 3).
Control
Conventional LLINs that contain pyrethroid only. Nets could be
treated with the same insecticide at diCerent doses from the
intervention net to allow critical appraisal of all pyrethroid-
PBO nets currently in development or on the market. For both
intervention and control arms, nets could be unholed, holed,
unwashed, or washed, provided the trials adhered to WHO
guidelines (WHO 2013).
Types of outcome measures
Trials had to include at least one of the following primary outcomes
to be eligible for inclusion.
Primary outcomes
Epidemiological
1. Parasite prevalence: presence of malaria parasites detected
through microscopy of blood or rapid diagnostic tests (RDTs)
2. Incidence of clinical malaria: clinical diagnosis based on
participants' symptoms and on physical findings at examination
Entomological
1. Mosquito mortality: immediate death or delayed death (up to
24 hours), or both, measured as a proportion of total mosquito
number. A mosquito is classified as dead if it is immobile, cannot
stand or fly, or shows no sign of life
2. Mosquito knock-down: mosquito ‘mortality' recorded one hour
post insecticide exposure, termed ‘knock-down', as some
mosquitoes may recover during the 24-hour recovery period
before mosquito mortality is recorded at 24 hours post exposure
3. Blood-feeding success: number of mosquitoes that have blood-
fed (alive or dead)




1. Deterrence: the number of mosquitoes that enter a hut that
is using a pyrethroid-PBO net relative to the number of
mosquitoes found in a control hut that is using a standard LLIN
(experimental hut trials only)
2. Exophily: the proportion of mosquitoes found in exit/veranda
traps of a hut that is using a pyrethroid-PBO net relative to the
control hut that is using a standard LLIN (experimental hut trials
only)
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3. Mosquito density: measured by all standard methods, such
as window exit traps, indoor resting collections, floor sheet
collections, pyrethrum spray catch, and light traps (village trials)
4. Parity rate: percentage of parous mosquitoes detected by
mosquito ovary dissections (village trials)
Search methods for identification of studies
We identified all relevant trials regardless of language or
publication status (published, unpublished, in press, and in
progress). We have presented the search strategies in Appendix 1.
Electronic searches
Vittoria Lutje, the Cochrane Infectious Diseases Group (CIDG)
Information Specialist, searched the following databases on 25
September 2020 using the search terms and strategy described in
Appendix 1: the CIDG Specialized Register; the Cochrane Central
Register of Controlled Trials (CENTRAL; 2018, Issue 8), included
in the Cochrane Library; MEDLINE (PubMed); Embase (OVID);
Web of Science Core Collection; and CAB Abstracts. She also
searched for trials in progress at the WHO International Clinical
Trials Registry Platform (WHO ICTRP; www.who.int/ictrp/en/) and
ClinicalTrials.gov (clinicaltrials.gov/ct2/home).
Searching other resources
We contacted the following organizations for unpublished data: the
PMI; the Innovative Vector Control Consortium (IVCC); Vestergaard
Frandsen; Sumitomo Chemical Company Ltd.; Vector Control
Innovations Private Ltd.; Endura SpA; and WHOPES. We checked the
reference lists of trials identified by the above methods.
Data collection and analysis
All analyses were stratified by trial design and mosquito insecticide
resistance level when possible. We performed analyses for the
primary outcomes stratified by follow-up time (4 to 6 months, 9 to
12 months, 16 to 18 months, and 21 to 25 months).
We determined whether mosquito populations are susceptible
or resistant to pyrethroid insecticides based on WHO definitions
(WHO 2016; Table 4). We used 24-hour mosquito mortality to
determine resistance status; however if this had been unavailable,
we intended to use knock-down 60 minutes aQer the end of the
assay. We stratified resistant populations into low-, moderate-, and
high-prevalence resistance groups (Table 5), by dividing resistant
mosquitoes (i.e. those with < 90% mortality) into three equal
groups, with the lower third being most resistant and the upper
third most susceptible.
Selection of studies
Two review authors (KG and NL or LC) independently screened titles
and abstracts of all retrieved references based on the inclusion
criteria (Table 6). We resolved any inconsistencies between review
authors' selections by discussion. If we were unable to reach an
agreement, we consulted a third review author (HR). We retrieved
full-text trial reports for all potentially relevant citations. Two
review authors independently screened the full-text articles and
identified trials for inclusion, and identified and recorded reasons
for exclusion of ineligible trials in a Characteristics of excluded
studies table. We resolved any disagreements through discussion
or, if required, we consulted a third review author (HR). We
identified and excluded duplicates and collated multiple reports of
the same trial, so that each trial, rather than each report, was the
unit of interest in the review. We recorded the selection process in
suCicient detail to complete a PRISMA flow diagram (Moher 2009).
Data extraction and management
AQer selection, we summarized all included trials according to
the tables in Appendix 2. Two review authors (KG and NL or LC)
independently extracted data from included trials using the pre-
designed data extraction form (Appendix 3). If data were missing
from an included trial, we contacted the trial authors to ask
for further information. We entered data into Review Manager 5
(RevMan 5) (Review Manager 2014).
Assessment of risk of bias in included studies
Two review authors (KG and NL or LC) independently assessed the
risk of bias of each included trial using a set of predetermined
criteria specific to each trial type adapted from Strode 2014
(Appendix 4). We assigned a classification of low, high, or unclear
risk of bias for each component. For all included trials, we assessed
whether any trial authors had submitted any conflicts of interest
that may have biased trial methods or results.
Randomized trials and village trials
We assessed 12 criteria for village and RCTs: recruitment
bias, comparability of mosquitoes between LLIN/pyrethroid-PBO
net households (e.g. species composition), collectors blinded,
household blinded, treatment allocation, allocation concealment,
incomplete outcome data, raw data reported, clusters lost to
follow-up, selective reporting, adjustment for data clustering, and
trial authors' conflicting interests.
Experimental hut trials
For experimental hut trials, we assessed 11 criteria: comparability
of mosquitoes between LLIN/pyrethroid-PBO net arms (e.g.
species composition), collectors blinded, sleepers blinded, sleeper
bias accounted for, treatment allocation, treatment rotation,
standardized hut design, hut cleaning between treatments,
incomplete outcome data, raw data reported, and trial authors'
conflicting interests.
Measures of treatment e<ect
For dichotomous data, we preferentially presented the risk ratio
(RR). For the outcome of parasite prevalence from cRCTs, we used
the odds ratio (OR) as the measure of eCect, as one study presented
adjusted ORs that could not be converted to adjusted RRs using
the standard formula presented in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011). We found no
continuous or count data; however if we had, we would have
used mean diCerences (MDs) and rate ratios, respectively. We have
presented all results with 95% confidence intervals (CIs).
Unit of analysis issues
For trials randomized by hut or village, we used the adjusted
measure of eCect reported in the paper if available. For the outcome
of parasite prevalence  from cRCTs, we converted adjusted RRs
presented in one study - Staedke 2020 - to adjusted ORs using
the standard formula presented in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011), so that this
study could be pooled with ProtopopoC 2018.
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When adjusted measures of eCect were not reported, we used an
intracluster correlation coeCicient (ICC) and average cluster size
to adjust the data ourselves (Higgins 2011 Section 16.3.4). If the
included trial did not report the ICC value, we estimated the ICC
value and performed sensitivity analyses to investigate the impact
of estimating the ICC. When ICCs have been used to adjust results
for clustering, forest plots for both hut and village trials show the
eCective number of events and the number of mosquitoes aQer
adjustments for clustering.
To adjust results of experimental hut trials for clustering, we treated
each ‘hut and night' combination as the unit of randomization,
as each hut was tested with each type of net over a series of
nights. Sleepers inside the huts were rotated each night, so by using
"hut/night" as the unit of randomization, sleeper eCects were also
accounted for. We calculated eCective sample sizes by estimating
an ICC and a corresponding design eCect. We divided both the
number of mosquitoes and the number experiencing the event by
this design eCect.
Dealing with missing data
In the case of missing data, we contacted trial authors to request
this information. If we had identified trials in which participants
were lost to follow-up, we would have investigated the impact
of missing data via imputation using a best/worst-case scenario
analysis.
When information on mosquito insecticide resistance was not
collected at the time of the trial, review authors determined a
suitable proxy. Proxy resistance data had to be taken from the same
area and conducted within three years of the trial, and the same
insecticide, dose, and mosquito species had to be used. More than
50 mosquitoes per insecticide should have been tested against an
appropriate control. When no resistance data were available, we
determined that resistance status was unclassified.
Assessment of heterogeneity
We presented the results of included trials in forest plots, which
we inspected visually, to assess heterogeneity (i.e. non-overlapping
CIs generally signify statistical heterogeneity). We used the Chi2 test
with a P value less than 0.1 to indicate statistical heterogeneity. We
quantified heterogeneity by using the I2 statistic (Higgins 2003), and
we interpreted a value greater than 75% to indicate considerable
heterogeneity (Deeks 2017).
Assessment of reporting biases
To analyse the possibility of publication bias, we intended to
use funnel plots if 10 trials with epidemiological endpoints were
included in any of the meta-analysis. However, no analyses
included 10 or more trials, so this plan was not applicable.
Data synthesis
When appropriate, we pooled the results of included trials using
meta-analysis. We stratified results by type of trial, mosquito
resistance status, and net type (i.e. by product, e.g. Olyset Plus).
Four review authors (KG, NL, LC, and MC) analysed the data using
RevMan 5 (Review Manager 2014), using the random-eCects model
(if we detected heterogeneity; or if the I2 statistic value was greater
than 75%) or the fixed-eCect model (for no heterogeneity; or if the
I2 statistic value was less than 75%). The exception to this is that for
the primary outcome of parasite prevalence from cluster trials, we
pooled results using the fixed-eCect model, although heterogeneity
between study results was substantial. For additional information,
see 'ECects of Interventions: Epidemiological results'. We would
have refrained from pooling trials in meta-analysis if it was not
clinically meaningful to do so, due to clinical or methodological
heterogeneity.
Subgroup analysis and investigation of heterogeneity
We performed subgroup analyses according to whether nets were
washed or unwashed.
Sensitivity analysis
We intended to perform sensitivity analyses to determine the
eCect of exclusion of trials that we considered to be at high risk
of bias; however this approach was not applicable, as no trials
were deemed at high risk. We would have performed a sensitivity
analysis for missing data during imputation with best/worst-case
scenarios, but again this was not applicable.
We performed sensitivity analyses to investigate the impact of
estimating an ICC to adjust trial results for clustering. We performed
analyses using ICCs of 0.01, 0.05, and 0.1. Because results were
robust to these adjustments, we used the most conservative ICC
(0.1), and we adjusted all results from unadjusted cluster trials
using this ICC. We have not presented analyses using the smaller
ICCs (0.01 and 0.05).
Summary of findings and assessment of the certainty of the
evidence
We assessed the certainty of evidence using the GRADE approach
(Schünemann 2013). We constructed ‘Summary of findings' tables
using GRADEpro Guideline Development Tool (GDT) soQware
(GRADEpro GDT 2015).
R E S U L T S
Description of studies
Results of the search
We identified 389 records through our searches. We removed
duplicates, leaving 347  records, and we screened all articles for
possible inclusion. AQer abstract and title screening, we excluded
322 ineligible trials. We assessed 25 full-text articles for eligibility
and excluded nine articles for the following reasons: three trials did
not share full data sets, two were laboratory studies, and four are
ongoing. Sixteen trials met the inclusion criteria (Figure 1).
 
Piperonyl butoxide (PBO) combined with pyrethroids in insecticide-treated nets to prevent malaria in Africa (Review)










Cochrane Database of Systematic Reviews
Figure 1.   Study flow diagram.
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Figure 1.   (Continued)
 
Included studies
Sixteen trials met the inclusion criteria; we have described them
in the Characteristics of included studies tables. Ten trials were
experimental hut trials (Bayili 2017 (Burkina Faso); Corbel 2010
(Burkina Faso, Benin, Cameroon); Koudou 2011 (Côte d'Ivoire);
Menze 2020 (Cameroon); Moore 2016 (Tanzania); N'Guessan 2010
(Benin); Oumbouke 2019 (Côte d'Ivoire); Pennetier 2013 (Benin);
Toé 2018 (Burkina Faso); Tungu 2010 (Tanzania)). Four trials
were village trials (Awolola 2014 (Nigeria); Cisse 2017 (Mali);
Mzilahowa 2014 (Malawi);  Stiles-Ocran 2013 (Ghana)). Two were
cRCTs (ProtopopoC 2018 (Tanzania); Staedke 2020 (Uganda)). All
trials were conducted in Africa.
Interventions
Six trials compared Permanet 2.0 to Permanet 3.0 (Awolola 2014;
Corbel 2010; Koudou 2011; N'Guessan 2010; Stiles-Ocran 2013;
Tungu 2010); two trials compared Olyset Net to Olyset Plus
(Pennetier 2013; ProtopopoC 2018); two trials compared MAGNet
LN to Veeralin LN (Moore 2016; Oumbouke 2019); five trials
compared both Olyset Net to Olyset Plus and Permanet 2.0 to
Permanet 3.0 (Cisse 2017; Menze 2020; Mzilahowa 2014; Staedke
2020; Toé 2018); and one trial compared DawaPlus 2.0 to DawaPlus
3.0 and DawaPlus 4.0 (Bayili 2017).
Excluded studies
We assessed 25  full-text articles for eligibility and excluded
nine  articles for the following reasons: three  trials are awaiting
classification because we were unable to obtain the full data
sets aQer we contacted trial authors (see Characteristics of
studies awaiting classification table);  four trials are ongoing (see
Characteristics of ongoing studies section); and two trials included
only laboratory data (Darriet 2011; Darriet 2013).
Risk of bias in included studies
We have provided a ‘Risk of bias' assessment summary in Figure 2.
The criteria we used to assess risk of bias are provided in Appendix
5 (experimental hut trials) and in Appendix 6 (village trials).
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Awolola 2014 + ? - + + + + + + + - +
Bayili 2017 + ? ? + + + + ? + + +
Cisse 2017 + ? - + + + + + + + - +
Corbel 2010 + ? ? + + + + ? + + +
Koudou 2011 + ? ? + + + + + + + +
Menze 2020 + ? ? + + + + + + + + +
Moore 2016 + ? ? + + + + ? + + +
Mzilahowa 2014 + ? - + + + + + + + - ?
N'Guessan 2010 + ? ? + + + + + + + ?
Oumbouke 2019 + ? ? + + + + + + + + +
Pennetier 2013 + ? ? + + + + + + + +
Protopopoff 2018 + ? + + + + + + + + + +
Staedke 2020 + ? - + + + + + ? + + +
Stiles-Ocran 2013 + ? - + + + + + + + - ?
Toé 2018 + ? ? + + + + ? + + +
Tungu 2010 + ? ? + + + + + + + +
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Allocation
Recruitment bias
We assessed all four village trials as having low risk of recruitment
bias, as recruitment bias is related to human participants and so is
not applicable to this review (Awolola 2014; Cisse 2017; Mzilahowa
2014; Stiles-Ocran 2013). We assessed the two cRCTs as having
low risk, as no participants were recruited aQer clusters had been
randomized (ProtopopoC 2018; Staedke 2020).
Mosquito group comparability
We judged all 10  experimental hut trials to be at low risk
(Bayili 2017; Corbel 2010; Koudou 2011; Menze 2020; Moore 2016;
N'Guessan 2010; Oumbouke 2019; Pennetier 2013; Toé 2018; Tungu
2010), as the huts were situated in the same trial area and therefore
were accessible to the same mosquito populations. We judged
all four village trials and both cRCTs to be at unclear risk, as for
six trials, species composition and resistance status varied slightly
between treatment arms (Awolola 2014; Cisse 2017; Menze 2020;
Oumbouke 2019; ProtopopoC 2018; Stiles-Ocran 2013); for one
trial, species and resistance data were not separated by village
(Mzilahowa 2014); and for one trial, the size of the area covered
made it diCicult to classify resistance status in all areas (Staedke
2020).
Blinding
We assessed the 10 hut trials to be at unclear risk, as they did not
specify whether observers, collectors and sleepers (hut trials) were
blinded (Bayili 2017; Corbel 2010; Koudou 2011; Menze 2020; Moore
2016; N'Guessan 2010; Oumbouke 2019; Pennetier 2013; Toé 2018;
Tungu 2010). This is not standard protocol for these trial designs
and is thought unlikely to aCect the results. We judged four village
trials to be at high risk of bias, as it was not stated whether collectors
were blinded, and this may have aCected searching eCorts during
collection (Awolola 2014; Cisse 2017; Mzilahowa 2014; Stiles-Ocran
2013). We judged one cRCT as having high risk, as it was stated
that LLIN allocation was not masked to collectors (Staedke 2020),
and the other as having low risk because collectors were masked to
treatment (ProtopopoC 2018). For household blinding, we judged
all four village trials and both cRCTs to be at low risk of bias. Four
village trials and one cRCT did not state whether households were
blind to the intervention; however this was unlikely to influence
the results (Awolola 2014; Cisse 2017; Mzilahowa 2014; Stiles-Ocran
2013; Staedke 2020). We judged one cRCT as having low risk, as
inhabitants and field collectors were blinded to intervention arms
(ProtopopoC 2018).
Sleeper bias
We assessed the 10 hut trials to be at low risk for sleeper bias, as
sleepers were rotated between huts according to a Latin square
design (Bayili 2017; Corbel 2010; Koudou 2011; Menze 2020; Moore
2016; N'Guessan 2010; Oumbouke 2019; Pennetier 2013; Toé 2018;
Tungu 2010).
Treatment allocation, rotation, and concealment
We assessed the 10  hut trials to be at low risk for treatment
allocation and rotation, as treatments were rotated between
huts according to a Latin square design (Bayili 2017; Corbel
2010; Koudou 2011; Menze 2020; Moore 2016; N'Guessan 2010;
Oumbouke 2019; Pennetier 2013; Toé 2018; Tungu 2010). We
assessed all four village trials and both cRCTs to be at low risk for
treatment allocation (Awolola 2014; Cisse 2017; Mzilahowa 2014;
ProtopopoC 2018; Staedke 2020; Stiles-Ocran 2013), as villages
were randomly assigned to treatment arms. We assessed all
four village trials and both cRCTs as having low risk of bias for
allocation concealment (Awolola 2014; Cisse 2017; Mzilahowa 2014;
ProtopopoC 2018; Staedke 2020; Stiles-Ocran 2013).
Hut design
We assessed all 10  hut trials to be at low risk of bias, as huts
were built to standard West or East African specifications (Bayili
2017; Corbel 2010; Koudou 2011; Menze 2020; N'Guessan 2010;
Oumbouke 2019; Pennetier 2013; Toé 2018; Tungu 2010), or they
used modified but standardized designs (Moore 2016).
Cleaning
We assessed four hut trials to be at unclear risk, as they did not
state whether huts were cleaned between treatment arms (Bayili
2017; Corbel 2010; Moore 2016; Toé 2018). We assessed six to be at
low risk, as cleaning was conducted between treatment rotations
(Koudou 2011; Menze 2020; N'Guessan 2010; Oumbouke 2019;
Pennetier 2013; Tungu 2010).
Incomplete outcome data
We assessed all hut trials - Bayili 2017; Corbel 2010; Koudou
2011; Menze 2020; Moore 2016; N'Guessan 2010; Oumbouke 2019;
Pennetier 2013; Toé 2018; Tungu 2010, village trials - Awolola
2014; Cisse 2017; Mzilahowa 2014; Stiles-Ocran 2013, and cRCTs
- ProtopopoC 2018; Staedke 2020 - to be at low risk for both
incomplete outcome data and raw data reporting, as there were
no incomplete outcome data, or missing data were later provided
by trial authors. In cases when raw data were not reported, we
were able to calculate them from the percentages and sample sizes
given. When these data were not available, we did not include the
trials.
Clustering bias
Staedke 2020 lost 14 clusters to follow-up at the latest time point
and was therefore assessed as having unclear risk of bias. In the
other village and cRCT trials, no clusters were lost to follow-up, and
these trials were assessed as having low risk (Awolola 2014; Cisse
2017; Mzilahowa 2014; ProtopopoC 2018; Staedke 2020; Stiles-
Ocran 2013). We assessed four village trials as having high risk
of bias for statistical methods used, as they did not adjust for
clustering (Awolola 2014; Cisse 2017; Mzilahowa 2014; Stiles-Ocran
2013). We assessed the two cRCTs as having low risk of bias, as they
took clustering into account and adjusted for it in their statistical
methods (ProtopopoC 2018; Staedke 2020).
Selective reporting
We assessed all village trials and cRCTs as having low risk of bias
regarding selective reporting, as they appear to have reported all
measured outcomes (Awolola 2014; Cisse 2017; Mzilahowa 2014;
ProtopopoC 2018; Staedke 2020; Stiles-Ocran 2013).
Other potential sources of bias
Conflicting interests
We judged nine hut trials - Bayili 2017; Corbel 2010; Koudou 2011;
Menze 2020; Moore 2016; Oumbouke 2019; Pennetier 2013; Toé
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2018; Tungu 2010, two village trials - Awolola 2014; Cisse 2017, and
both cRCTs - ProtopopoC 2018; Staedke 2020 - as having low risk, as
trial authors reported no conflicting interests. We assessed one hut
trial to be at unclear risk (N'Guessan 2010), as trial authors stated
that they had received funding from LLIN manufacturers when
conducting the trials, and the same funders provided comments
on the manuscript. We assessed one village trial as having unclear
risk, as trial authors did not state whether there were conflicting
interests (Mzilahowa 2014), and another trial as having unclear
risk, as the trial was conducted to form part of the manufacturer's
product dossier (Stiles-Ocran 2013).
E<ects of interventions
See: Summary of findings 1 Summary of findings table 1;
Summary of findings 2 Summary of findings table 2; Summary of
findings 3 Summary of findings table 3; Summary of findings 4
Summary of findings table 4
We compared the eCects of pyrethroid-PBO nets currently in
commercial development or on the market with their non-PBO
equivalent in relation to malaria infection and entomological
outcomes. This review is based on results from 16 trials.
Epidemiological results
Two trials examined the eCects of pyrethroid-PBO nets (Olyset
Plus and PermaNet 3.0) on parasite prevalence (ProtopopoC 2018;
Staedke 2020). Pooling the latest endpoint aQer the intervention
from both trials revealed that parasite prevalence was decreased in
the intervention arm (Olyset Plus and PermaNet 3.0) (OR 0.79, 95%
CI 0.67 to 0.95; 2 trials, 2 comparisons; Analysis 1.1).
There was little variation of eCect from the earliest time point (4 to
6 months aQer: OR 0.74, 95% CI 0.62 to 0.89) to the latest time point
(21 to 25 months aQer: OR 0.79, 95% CI 0.67 to 0.95) (Analysis 1.2).
We used a fixed-eCect model to pool data from the two studies.
Although heterogeneity between study results was considerable,
both studies demonstrated clear beneficial eCects with PBO
nets. Performing random-eCects meta-analysis accounted for
diCerences between study results to the extent that identified




Ten experimental hut trials (phase 2 trials) examined the eCects
of pyrethroid-PBO nets on mosquito mortality, blood feeding,
exophily, and deterrence (Bayili 2017; Corbel 2010; Koudou 2011;
Menze 2020; Moore 2016; N'Guessan 2010; Oumbouke 2019;
Pennetier 2013; Toé 2018; Tungu 2010). We subgrouped the data
by net washing into unwashed and washed groups. All washed
nets were washed 20 times according to WHO specifications (WHO
2013). We pooled the results initially and then stratified them by
insecticide resistance level and by net type. Two trials did not wash
their nets and so did not report any data for the washed subgroup
(Menze 2020 Toé 2018). One trial did not introduce holes into the
nets and so did not report blood-feeding success data (Koudou
2011).
Pooled analysis
Pooled analysis of all experimental hut trials using both unwashed
nets - Bayili 2017; Corbel 2010; Koudou 2011; Menze 2020; Moore
2016; N'Guessan 2010; Oumbouke 2019; Pennetier 2013; Toé 2018;
Tungu 2010 - and washed nets - Bayili 2017; Corbel 2010; Koudou
2011; Moore 2016; N'Guessan 2010; Oumbouke 2019; Pennetier
2013; Tungu 2010 - revealed that pyrethroid-PBO nets significantly
increased mosquito mortality by 43% (risk ratio (RR) 1.43, 95%
confidence interval (CI) 1.26 to 1.62) and reduced blood-feeding
success by 25% (RR 0.75, 95% CI 0.66 to 0.85). The magnitude of the
eCect was reduced by net washing. Unwashed pyrethroid-PBO nets
increased mosquito mortality by 63% compared to unwashed LLINs
(RR 1.63, 95% CI 1.29 to 2.05; 10 trials, 18 comparisons; Analysis 2.1);
when nets were washed, this eCect was decreased to 19% (RR 1.19,
95% 1.04 to 1.38; 8 trials, 12 comparisons; Analysis 2.1). Unwashed
pyrethroid-PBO nets reduced mosquito blood-feeding success by
32% (RR 0.68, 95% CI 0.57 to 0.80; 9 trials, 17 comparisons;
Analysis 2.2; Bayili 2017; Corbel 2010; Moore 2016; N'Guessan 2010;
Pennetier 2013; Toé 2018; Tungu 2010); however this eCect was
lost when nets were washed (7 trials, 11 comparisons; Analysis 2.2;
Bayili 2017; Corbel 2010; Moore 2016; N'Guessan 2010; Pennetier
2013; Tungu 2010). There was no eCect on mosquito exophily in
either unwashed (10 trials, 17 comparisons; Analysis 2.3) or washed
groups (8 trials, 12 comparisons; Analysis 2.3). Mosquito deterrence
data were presented relative to an untreated control and hence are
not included as a forest plot. There was considerable variation in
deterrence rates but no clear relationship with resistance level, net
type, or washing status (Table 7).
Heterogeneity in this pooled analysis was considerable, particularly
for estimates of mortality. We therefore performed a pre-specified,
stratified analysis, dividing the results into trials conducted in areas
of low, moderate, or high resistance in the Anopheles population.
Stratified analysis: mosquito resistance status
We used WHO and Centers for Disease Control and Prevention
(CDC) definitions of mosquito mortality from WHO tube assays or
CDC bottle tests to classify mosquito resistance (Table 4). Both tests
define mosquitoes as resistant when mortality is less than 90%. We
further stratified resistance based on the following mortality levels:
< 30%, high resistance; 31% to 60%, moderate resistance; and 61%
to 90%, low resistance (Table 5). When resistance data were not
collected at the time of the trial, we identified a suitable proxy
based on previously described criteria (see Dealing with missing
data section); when we could not identify a suitable proxy, we
deemed the trial as ‘unclassified' and did not include it in the
resistance stratification.
Five trials were conducted in four areas where mosquito
populations exhibited high resistance to pyrethroids (Bayili 2017;
Corbel 2010; Koudou 2011; Pennetier 2013; Toé 2018). Under these
conditions, unwashed pyrethroid-PBO nets increased mosquito
mortality by 84% in comparison to unwashed LLINs (RR 1.84, 95%
CI 1.60 to 2.11; 5 trials, 9 comparisons; Analysis 2.4); however this
eCect was lost when nets were washed (4 trials, 5 comparisons;
Analysis 2.4; Bayili 2017; Corbel 2010; Koudou 2011; Pennetier
2013). Blood-feeding success was reduced by 40% in unwashed
pyrethroid-PBO net groups compared to unwashed LLIN groups (RR
0.60, 95% CI 0.50 to 0.71; 4 trials, 8 comparisons; Analysis 2.5; Bayili
2017; Corbel 2010; Pennetier 2013; Toé 2018), and was reduced by
19% when nets were washed (RR 0.81, 95% CI 0.72 to 0.92; 3 trials,
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4 comparisons; Analysis 2.5; Bayili 2017; Corbel 2010; Pennetier
2013).
Two trials at three diCerent sites were conducted in areas with
moderate insecticide resistance (Menze 2020; N'Guessan 2010).
With unwashed nets, mosquito mortality was increased by 68% in
comparison to mosquito mortality with unwashed LLINs (RR 1.68,
95% CI 1.33 to 2.11; 2 trials, 3 comparisons; Analysis 2.6); however
there was minimal eCect on blood-feeding success. No eCect on
mosquito mortality (1 trial, 1 comparison; Analysis 2.6) or on blood-
feeding success (1 trial, 1 comparison; Analysis 2.7) was observed
with washed treatments.
Two trials at three diCerent sites were conducted in areas with low
insecticide resistance (Corbel 2010; Oumbouke 2019). A small eCect
on mosquito mortality was observed with unwashed nets (RR 1.25,
95% CI 0.99 to 1.57; 2 trials, 3 comparisons; Analysis 2.8) and was
also seen with washed nets (RR 1.30, 95% CI 0.95 to 2.04; 2 trials, 3
comparisons; Analysis 2.8). No eCect on blood-feeding success was
noted (2 trials, 3 comparisons; Analysis 2.9).
At susceptible sites (Moore 2016; Tungu 2010), no eCect on
mosquito mortality (2 trials, 2 comparisons; Analysis 2.10) nor on
blood-feeding success (2 trials, 2 comparisons; Analysis 2.11) was
observed.
Stratified analysis: net type
AQer stratifying by resistance status, we performed a secondary
analysis stratified according to net type. Due to the limited number
of trials, we performed this analysis only for trials using PermaNet
3.0 or Olyset Plus. Although additional trials utilising Veeralin LN,
DawaPlus 3.0, and DawaPlus 4.0 have been conducted, not all
data were made available to us for the purposes of this Cochrane
Review. Futhermore, the analysis was restricted to trials conducted
in areas of high resistance, as this analysis indicated an impact of
only pyrethroid-PBO nets in these settings. Three trials compared
PermaNet 2.0 (LLIN) to PermaNet 3.0 (pyrethroid-PBO nets), and
two compared Olyset Nets (LLIN) to Olyset Plus (pyrethroid-PBO
nets).
In the PermaNet group, in high-resistance settings, unwashed
PermaNet 3.0 increased mosquito mortality by 81% compared to
PermaNet 2.0 (RR 1.81, 95% CI 1.56 to 2.10; 3 trials, 4 comparisons;
Analysis 2.12; Corbel 2010; Koudou 2011; Toé 2018). AQer washing,
there was no significant increase in mortality in the PermaNet 3.0
arm (2 trials, 2 comparisons; Analysis 2.12; Corbel 2010; Koudou
2011). Blood-feeding success was reduced by 47% when unwashed
PermaNet 3.0 was used (RR 0.53, 95% CI 0.40 to 0.69; 2 trials,
3 comparisons; Analysis 2.13; Corbel 2010; Toé 2018); only one
trial was available for washed nets (Corbel 2010), and in this trial,
PermaNet 3.0 also reduced blood-feeding success (RR 0.76, 95%
0.61 to 0.93; 1 trial, 1 comparison; Analysis 2.13).
In high-resistance settings, Olyset Plus increased mosquito
mortality by 72% when nets were unwashed (RR 1.72, 95% CI 1.48
to 1.99; 2 trials, 3 comparisons; Analysis 2.14; Pennetier 2013; Toé
2018). Only one trial compared washed Olyset Plus with washed
Olyset (Pennetier 2013); in this trial, enhanced mortality (81%) was
still observed in the Olyset Plus arm aQer washing (RR 1.81, 95%
CI 1.25 to 2.61; 1 trial, 1 comparison; Analysis 2.14). There was no
impact on blood-feeding success when unwashed Olyset Plus was
compared with Olyset (2 trials, 3 comparisons; Analysis 2.15); the
single trial that looked at washed Olyset Plus showed decreased
blood feeding compared to Olyset (RR 0.50, 95% 0.27 to 0.93; 1 trial,
1 comparison; Analysis 2.15).
Village trials
In the village trials, there was no decrease in sporozoite rate in
trial arms receiving pyrethroid-PBO nets (RR 0.82, 95% CI 0.24
to 2.75; 4 trials, 5 comparisons; Analysis 1.3; Awolola 2014; Cisse
2017; ProtopopoC 2018; Stiles-Ocran 2013). Mosquito parity was
not reduced in pyrethroid-PBO villages (3 trials, 4 comparisons;
Analysis 1.4; Cisse 2017; Mzilahowa 2014; Stiles-Ocran 2013). It was
not possible to stratify these data by resistance status due to the
variability in resistance levels between villages within the same
trial. Mosquito density was measured by a variety of methods and
was summarized in diCerent ways (e.g. mean number caught per
house, mean number caught per village). When baseline data were
collected, we calculated a percentage reduction. Higher reductions
in mosquito densities were observed in pyrethroid-PBO net villages
compared to LLIN villages (Table 8).
D I S C U S S I O N
See Summary of findings 1, Summary of findings 2, Summary of
findings 3, and Summary of findings 4.
Summary of main results
Two cluster-randomized controlled trials (cRCTs) were performed
on pyrethroid-piperonyl butoxide (PBO) nets. The first trial, which
compared parasite prevalence in children using Olyset Plus nets
with that in children using Olyset nets, in a region of Tanzania
where mosquito vectors are highly resistant to pyrethroids, found
that pyrethroid-PBO nets reduced parasite prevalence by 60% at
the final time point (21 months) (ProtopopoC 2018). The second
cRCT compared parasite prevalence in children using Olyset Plus or
Permanet 3.0 nets with that in children using Olyset or Permanet
2.0 nets across East and West Uganda, where mosquito vectors are
also highly resistant to pyrethroids, and found that pyrethroid-PBO
nets reduced parasite prevalence by 17% at the latest time point (25
months) (Staedke 2020).
All other trials included in this review measured entomological
endpoints. Four village trials measured sporozoite rates in
mosquitoes collected from houses using pyrethroid-PBO nets
and standard pyrethroid long-lasting insecticidal nets (LLINs), but
the results were highly heterogeneous and no evidence suggests
that pyrethroid-PBO nets reduced the mosquito infection rate
derived from this pooled analysis (Awolola 2014; Cisse 2017;
ProtopopoC 2018; Stiles-Ocran 2013). Similarly, the proportion of
parous mosquitoes (i.e. mosquitoes that have survived past one
gonotrophic cycle; used as an indirect measure of longevity) was
not significantly aCected by the presence of pyrethroid-PBO nets
(Cisse 2017; Mzilahowa 2014; Stiles-Ocran 2013).
When we pooled the results from 10  experimental hut trials
(Bayili 2017; Corbel 2010; Koudou 2011; Menze 2020; Moore 2016;
N'Guessan 2010; Oumbouke 2019; Pennetier 2013; Toé 2018;
Tungu 2010), data showed improved performance of pyrethroid-
PBO LLINs over standard LLINs in both increasing mosquito
mortality and reducing blood feeding, but these results were highly
heterogeneous. Stratifying experimental hut data by resistance
levels in this population reduced heterogeneity. In areas where
mosquitoes are highly resistant to pyrethroids, pyrethroid-PBO
nets will reduce mosquito blood-feeding rates (i.e. users will be
Piperonyl butoxide (PBO) combined with pyrethroids in insecticide-treated nets to prevent malaria in Africa (Review)










Cochrane Database of Systematic Reviews
better protected against mosquito bites by using pyrethroid-PBO
nets). This impact on blood feeding is reduced when nets have
been through the standard 20 washes recommended by the World
Health Organization (WHO) to assess chemical durability, but
it remains significant (high-certainty evidence). When resistance
is high and new unwashed nets are used, mosquito mortality
is substantially higher when the nets contain PBO compared
to pyrethroid only (high-certainty evidence). However this eCect
on mosquito mortality, which is important for the community-
level protection aCorded by LLIN usage (Hawley 2003; Maxwell
2002), is not sustained when nets have been washed multiple
times. In this Cochrane Review, we classified mosquitoes as highly
resistant if less than 30% were killed in a standard bioassay. When
mortality rates exceeded 30%, we found little evidence to suggest
that pyrethroid-PBO nets provided greater personal protection or
resulted in greater mosquito mortality than standard pyrethroid-
only nets. This result is not unexpected, given that in areas where
resistance is uncommon or absent, exposure to pyrethroids alone
would be expected to negatively aCect the mosquito; it is only in
areas where the eCicacy of pyrethroids has been eroded by the
development of high levels of resistance that the addition of a
synergist might be needed.
We found no evidence for any diCerence in the performance of
pyrethroid-PBO nets from diCerent manufacturers against highly
pyrethroid-resistant mosquitoes. We stratified results by net type
only for trials that were conducted in areas of high resistance. We
have not reported comparisons for DawaPlus-PBO and Veeralin-
PBO nets in this sub-analysis, as there was only a single data point
for these net types. We did not stratify data from the cRCTs by net
type, as one trial used only one net type (ProtopopoC 2018), and
the second was not powered to detect diCerences between nets
from diCerent manufacturers and assigned an uneven number of
clusters to each net type (Staedke 2020). Unwashed PermaNet 3.0
and Olyset Plus resulted in similar increases in mosquito mortality
compared to pyrethroid-only LLINs from the same manufacturer,
although this eCect on mortality was not always sustained aQer
washing (Corbel 2010; Koudou 2011; Pennetier 2013; Toé 2018).
A significant improvement in personal protection for unwashed
pyrethroid-PBO nets was observed only for PermaNet 3.0 (Corbel
2010; Toé 2018), but aQer washing, pyrethroid-PBO nets from
both manufacturers provided greater personal protection than
the equivalent pyrethroid-only nets (Corbel 2010; Pennetier 2013).
Results from comparisons between pyrethroid-PBO nets from
diCerent manufacturers should be taken with great caution, given
the very limited number of data points available, particularly
for washed nets. Further trials, in which nets from diCerent
manufacturers are directly compared in the same trial, are needed
to address the issue of equivalence between diCerent pyrethroid-
PBO nets.
Certainty of the evidence
We appraised the certainty of evidence using the GRADE approach
(Summary of findings 1 Summary of findings 2 Summary of
findings 3 Summary of findings 4). The two cRCTs provided
moderate-certainty evidence that pyrethroid-PBO nets reduced
parasite  prevalence for the duration of the trial (high-certainty
evidence aQer four to six months) (ProtopopoC 2018; Staedke
2020).
This result was obtained from two independent studies, conducted
in diCerent locations and settings; therefore the evidence adheres
to the WHO recommendation that at least two cRCTs must be
completed to demonstrate public health value (WHO-GMP 2017b).
The certainty of evidence from trials using entomological endpoints
varied. Data from village trials were diCicult to assess, as there was
considerable heterogeneity in the level of pyrethroid resistance and
presumably also in the resistance mechanisms, both within and
between trials. Analysis of data from experimental hut trials yielded
high-certainty evidence for superior performance of pyrethroid-
PBO nets in areas of high resistance, but evidence from trials
conducted in other settings was of low or very low certainty.
Overall completeness and applicability of evidence
All trials included in this review compared pyrethroid-PBO nets
with the nearest equivalent pyrethroid-only LLINs. Further changes
to net specifications were oQen included when manufacturers
incorporated the synergist. For example, the pyrethroid-PBO net
manufactured by Vestergaard (PermaNet 3.0) contains higher levels
of deltamethrin and yarn of a diCerent denier (thickness) compared
to the pyrethroid-only equivalent, PermaNet 2.0; the pyrethroid in
Olyset Plus (Sumitomo Chemical Co. Ltd.) is released from the yarn
at a diCerent rate than that in the Olyset nets. These additional
variations in chemical or physical composition, or both, of the nets
make it diCicult to directly assess the added value of the addition
of PBO. Furthermore, the concentration of PBO and its site of
application diCer markedly between nets received from diCerent
manufacturers. Two of the currently available pyrethroid-PBO nets
(PermaNet 3.0 and Tsara Plus 3.0) contain PBO only on the roof
of the netting, exploiting the behavioural patterns of host-seeking
mosquitoes to attempt to reach the net user by approaching from
above (Parker 2015), whilst the remaining pyrethroid-PBO nets
contain the synergist on all sides of the net. The amount of PBO
contained within the net diCers by a factor of 25-fold. It is not known
how net manufacturers selected the doses of PBO applied to the
netting.
With currently available data, it is not possible to draw any
conclusions on which strategy for producing pyrethroid-PBO
nets will prove the most eCective under field conditions. The
optimum PBO:pyrethroid ratio will likely diCer depending on the
level of resistance in the mosquito and underpinning resistance
mechanisms. Data from experimental hut trials suggest that the
PBO component of pyrethroid-PBO nets is lost aQer repeated
washing, as enhanced mortality caused by the synergist nets is
not maintained aQer 20 washes. As yet, no trials on the durability
of pyrethroid-PBO nets under operational conditions have been
published, although monitoring is under way. It is encouraging to
note that both RCTs of pyrethroid-PBO nets found that the superior
protective eCicacy of Olyset Plus compared to standard Olyset nets
was maintained at 21 months of use; the trial in Tanzania is being
extended to establish whether this eCect lasts the full duration of
an LLIN's intended 36-month life span. No plans are under way
to continue monitoring in the Uganda trial past the 25-month
collections (Staedke 2020).
Most available data evaluated the performance of pyrethroid-
PBO LLINs against Anopheles gambiae s.l., with very limited data
available for the second major species complex in Africa, An
funestus, and none for other minor vector species. As diCerent
mosquito species may diCer in their behaviour and in the strength
and underpinning mechanisms of pyrethroid resistance, this
represents an important data gap that may have implications for
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practice in areas where An gambiae complex is not the predominant
malaria vector.
Potential biases in the review process
As the addition of PBO to pyrethroid LLINs is expected to
enhance their performance only in areas where mosquitoes
are resistant to pyrethroid insecticides, it was important to
stratify the results by resistance status. To do this, we used
the WHO definition of resistance as mosquito populations with
less than 90% mortality in a discriminating dose assay (WHO
2016), and then we split the resistant populations into three
groups, depending on the percentage of mortality observed.
Discriminating dose assays provide an estimate of the prevalence
of resistance in a population but do not indicate the strength
of this resistance nor give any indication of the mechanism(s)
underpinning the resistance. As PBO works primarily by inhibiting
the metabolism of pyrethroids by cytochrome P450s, this synergist
is likely to have had greatest impact in populations where
resistance was primarily conferred by elevated P450 activity and
further stratification according to resistance mechanisms might
have proved informative. However, in reality, characterization of
resistance in mosquitoes is still primarily performed by bioassays
alone and the relevant contributions of diCerent resistance
mechanisms to the phenotype remain unknown. An exception
to this is seen in An funestus, where pyrethroid resistance is
almost entirely due to elevated P450 activity (Churcher 2016).
Unfortunately, only one data set from experimental hut trials
conducted where An funestus was the primary vector was made
available to us at the time of this review.
Other examples of missing data that may have influenced study
results include the absence of data on resistance status in some
settings. Three experimental hut trials did not measure resistance
at the time of the trial (Moore 2016; N'Guessan 2010; Pennetier
2013). For two of these trials, we used proxies for resistance;
however, no proxy data were available for An funestus in Moore
2016, and hence we did not include this population in the stratified
analysis. Three trials did not share their data with the review
authors; these included trials on nets from two of the more recent
manufacturers to produce pyrethroid-PBO nets (N’Guessan 2016;
Tungu 2017), which precluded stratified analysis for these net
types. For clinical trials, both species composition and resistance
level may vary between clusters and/or over the duration of the trial
(e.g. the Uganda trial - Staedke 2020 - involved 104 clusters across
the country as part of the national LLIN campaign). The population
was classified as highly pyrethroid resistant based on data provided
by the study authors (WHO tube bioassay conducted in Banangaizi
East: deltamethrin 0.05%, 20.7% mosquito mortality, n = 163), but
the resistance phenotype of the vector population is likely to vary
considerably between clusters.
One key finding of this trial was the decline in performance
of pyrethroid-PBO nets aQer washing. However, as discussed
above, it is not clear how the standardized washing protocol
employed in experimental hut trials of LLINs reflects the actual
chemical retention of active ingredients under operational use. It
is encouraging to note that the impact of pyrethroid-PBO nets in
reducing parasite prevalence was sustained over two years, hence
the policy implications of the loss in bio eCicacy aQer washing
remain to be determined.
Agreements and disagreements with other studies or
reviews
This is an update of the first Cochrane Review of pyrethroid-
PBO nets (Gleave 2018). An earlier meta-analysis of experimental
hut data indicated that pyrethroid-PBO nets would have the
greatest impact against mosquito populations with intermediate
levels of resistance (Churcher 2016). Using transmission models
to convert entomological outputs into estimates of public health
benefit, the authors noted that the impact of pyrethroid-PBO
nets would vary depending on mosquito species, resistance
levels, parasite prevalence, and LLIN usage. The importance
of taking these key parameters into account when predicting
the public health impact of a switch to pyrethroid-PBO nets
has been somewhat lost in policy documents and operational
guidelines, which seek to provide a simple decision rule to aid
net selection. Hence, in the WHO report from the 2017 Evidence
Review Group on ‘Conditions for deployment of mosquito nets
treated with pyrethroid and piperonyl butoxide', it is recommended
that "National malaria control programmes and their partners
should consider deployment of pyrethroid-PBO nets in areas where
pyrethroid resistance has been confirmed in the main malaria
vectors" (WHO 2017). In technical guidelines from one of the major
net distributors, the PMI, the conditions for deployment of PBO
nets include "moderate levels of pyrethroid resistance (defined
as 35% to 80% mortality), evidence that PBO restores pyrethroid
susceptibility, and moderate to high malaria prevalence" (PMI
2018). The PMI definition of moderate resistance overlaps with
our definitions of moderate and low resistance. However in our
review, the best evidence for superior eCicacy of pyrethroid-PBO
nets is derived from areas with high resistance (< 30% mortality),
and very little evidence suggests improved performance in areas
with moderate or low levels of resistance. The diCerences between
these trials may have arisen from incorporation of a large data
set of laboratory bioassays comparing mosquito mortality with
or without pre-exposure to PBO in the modelling study. These
laboratory bioassays rely on use of a single discriminating dose
and identified multiple trials where highly resistant populations
were not impacted by PBO. In the current review, the mosquito
populations included were limited to sites in which experimental
hut trials had been conducted, and this may not have fully
captured the full diversity of resistance mechanisms in Anopheles
mosquitoes. This again highlights the importance of further trials
on the influence of resistance mechanisms on the impact of
pyrethroid-PBO LLINs.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
The findings of this review support the recent WHO policy
recommendation that pyrethroid-piperonyl butoxide (PBO) nets
should be considered for deployment in areas where pyrethroid
resistance has been confirmed in the main malaria vectors (WHO-
GMP 2017a). It is encouraging to note that both randomized
controlled  trials (RCTs)  of pyrethroid-PBO nets found that the
superior protective eCicacy of Olyset Plus compared to that of
standard Olyset nets was maintained at 21/25 months of use;
the Tanzania trial has been extended further to establish whether
this eCect lasts the full duration of an LLIN's intended 36-month
life span, but results are not yet publicly available. The WHO has
declared Olyset Plus as first-in-class for pyrethroid-PBO nets; as
a result, pyrethroid-PBO nets from other manufacturers will not
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be required to generate epidemiological evidence showing their
eCicacy.
When evaluating these trials, it is important to remember that the
PBO is an additive to the nets that is intended to increase their
eCicacy against pyrethroid-resistant mosquito populations. No
evidence suggests that pyrethroid-PBO nets are less eCective than
standard LLINs for inducing mosquito mortality in any setting. For
personal protection, blood-feeding rates are similarly decreased
under all resistance scenarios when unwashed PBO nets are used,
although this has not been shown for washed nets in low-resistance
or susceptible areas (low-certainty evidence). Hence if pyrethroid-
PBO nets perform as well as, or better than, standard LLINs, the
decision on whether to switch to nets incorporating the synergist is
largely a question of economics. With fixed budgets, there is a risk
that the target of universal coverage of LLINs may be more diCicult
to reach if more expensive pyrethroid-PBO nets are deployed.
Indeed, the WHO clearly states that countries should consider
deploying pyrethroid-PBO nets only in situations where coverage
with standard vector-control interventions is not reduced (WHO-
GMP 2017c). Trials of the cost-eCectiveness of pyrethroid-PBO nets
have not yet been possible due to uncertainties over the price
diCerential between pyrethroid-PBO nets and LLINs.
Implications for research
Experimental hut trials simultaneously comparing diCerent
pyrethroid-PBO nets in areas where mosquitoes have high levels
of pyrethroid resistance are needed to demonstrate equivalency
and to inform procurement decisions, particularly given the very
diCerent approaches used to incorporate PBO into LLINs employed
by diCerent manufacturers. The issue of durability of bioactive
levels of the synergist on the nets also needs further study; current
WHO protocols for measuring LLIN durability will need to be
adjusted to utilize pyrethroid-resistant colonies of mosquitoes, so
that the impact of PBO, and not just of the insecticide, can be
measured over the net's intended life span. The issue of the value
of entomological endpoints in estimating the public health value
of new types of nets remains contentious (Killeen 2018; WHO-
GMP 2017c). Performing experimental hut trials alongside future
randomized controlled trials of nets containing synergists, or other
novel active ingredients, would help resolve this issue.
In relation to reporting trial results, study authors need to record
the level of resistance in the local mosquito population at the time
of the trial and should include this when reporting the results.
Data on resistance mechanisms would also be of value toward a
improved understanding of how this influences the performance of
pyrethroid-PBO nets.
Limitations of this review
One of the problems in this research field is that pyrethroid-
PBO nets are commercial products. The pyrethroid-PBO nets
currently undergoing RCTs have had additional alterations made
to them, such as changing the concentration or rate at which the
pyrethroid is released. However, these are the products for which
policy decisions are needed that are based on evidence related
to their relative eCectiveness. Thus, in this Cochrane Review, we
examined the evidence concerning the eCectiveness of commercial
products. During these comparisons, we considered other potential
confounding factors.
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [author-defined order]
 
Study characteristics
Methods Cluster-randomized controlled village trial
Participants Households with at least 1 adult resident and 1 child aged 2 to 10 years, Anopheles species
Interventions Control: LLIN, PermaNet 2.0
Intervention: LLIN, PermaNet 3.0
Control: LLIN, Olyset Net
Intervention: LLIN, Olyset Plus
Outcomes Primary outcomes; parasite prevalence (proportion of thick blood smears that are positive for asexual
parasites) in children ages 2 to 10 years, assessed before net distribution and 3 times after nets are dis-
tributed
Secondary outcomes: prevalence of anaemia; mean haemoglobin in children ages 2 to 10 years; vector
density; measures of LLIN ownership; coverage, use, and integrity
Mosquito resistance status Resistance - high
Net treatment Nets unholed and unwashed
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Bias Authors' judgement Support for judgement
Recruitment bias Low risk No participants were recruited after clusters had been randomized
Were the mosquitoes
in LLIN and LLIN + PBO
groups comparable
Unclear risk Resistance monitoring was not conducted at all study sites due to the size of
the RCT
Collectors blinded High risk LLIN allocation was not masked; therefore risk of detection bias was high for
entomological outcomes





Low risk Randomization was used to allocate clusters to study groups
Allocation concealment
(selection bias)
Low risk Randomization was carried out to allocate treatments to clusters
Were incomplete out-
come data adequately ad-
dressed
Low risk No outcome data were incomplete; intention-to-treat analysis was conducted
Were the raw data report-
ed for LLIN and LLIN + PBO
groups
Low risk No outcome data were missing




Low risk All intended outcomes stated in the pre-published protocol were reported in
the final publication
Correct statistical meth-
ods; adjusted for cluster-
ing
Low risk Clustering was not taken into account and adjusted for during statistical










Participants Ilara - An gambiae (100% S-form)
Irolu - 95% An gambiae (100% S-form), 4.5% An arabiensis
Ijesa - 98.1% An gambiae (80% S-form, 19% M-form), 1.6% An arabiensis
Interventions Control: LLIN, PermaNet 2.0
Intervention: LLIN, PermaNet 3.0
Awolola 2014 
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Outcomes Mosquito mortality, blood feeding, sporozoite rate, mosquito density, parity rate
Mosquito resistance status Ilara - resistant - low (deltamethrin, 72.5% mortality, N = 120)
Irolu - resistant - low (deltamethrin, 62.5% mortality, N = 120)
Ijesa - resistant - low (deltamethrin, 66.7% mortality, N = 120)
Net treatment Nets unholed and unwashed
Location(s) Ilara, Nigeria - untreated net
Irolu, Nigeria - PermaNet 2.0
Ijesa, Nigera - PermaNet 3.0
Notes Trial conducted: March 2012 to March 2013
Risk of bias
Bias Authors' judgement Support for judgement
Recruitment bias Low risk Recruiment bias is related to human participants and so is not applicable to
this study
Were the mosquitoes
in LLIN and LLIN + PBO
groups comparable
Unclear risk Mosquito species composition varied slightly pre-trial and post-trial between
treatment villages. However, resistance level was the same
Collectors blinded High risk Not stated whether collectors where blinded; therefore judged as high risk, as
this is likely to impact searching efforts
Household blinded Low risk Unclear whether households were blinded – not stated in the publication. We




Low risk Villages were randomly assigned to treatment arms
Allocation concealment
(selection bias)
Low risk Allocation concealment procedures were not adhered to; however this is un-
likely to affect the results
Were incomplete out-
come data adequately ad-
dressed
Low risk There were no incomplete data
Were the raw data report-
ed for LLIN and LLIN + PBO
groups
Low risk All necessary data were reported
Clusters lost to follow-up Low risk No clusters were lost to follow-up
Selective reporting (re-
porting bias)
Low risk It appears that all measured outcomes were reported
Correct statistical meth-
ods; adjusted for cluster-
ing
High risk Study did not take clustering into account for statistical methods
Awolola 2014  (Continued)
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Trial authors' conflicting
interest
Low risk Trial authors declared no conflicting interests; however the study was funded
by Vestergaard (net manufacturers). Views and findings in the publication are





Methods Experimental hut trial
Participants An coluzzii
Interventions Control: LLIN, DawaPlus 2.0
Intervention: LLIN, DawaPlus 3.0, DawaPlus 4.0
Outcomes Mosquito mortality, blood feeding, deterrence, exophily
Mosquito resistance status Resistant - high (6% mortality, N = 98)
Net treatment Nets holed, nets unwashed and washed (x 20)
Location(s) Vallée du Kou, Burkina Faso
Notes Trial conducted: August 2016 to October 2016
Risk of bias
Bias Authors' judgement Support for judgement
Were the mosquitoes
in LLIN and LLIN + PBO
groups comparable
Low risk The hut trial was conducted in the same area; therefore characteristics are
similar
Collectors blinded Unclear risk Paper does not state whether collectors were blinded
Sleepers blinded Unclear risk Paper does not state whether sleepers were blinded




Low risk Treatments were not randomly allocated to huts; however the trial completed
a full rotation through the huts
Treatment rotation Low risk Treatments were rotated between huts according to a Latin square design + 2
weeks
Standardized hut design Low risk Huts were built previously according to standard West African design
Hut cleaning between
treatments
Unclear risk Trial authors do not state whether huts were cleaned between treatments
Were incomplete out-
come data adequately ad-
dressed
Low risk No data were incomplete
Bayili 2017 
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Were the raw data report-
ed for LLIN and LLIN + PBO
groups
Low risk All necessary data were reported
Trial authors' conflicting
interest






Participants An gambiae s.s.
Interventions Control: LLIN, Olyset Net, PermaNet 2.0
Intervention: LLIN, Olyset Plus, PermaNet 3.0
Outcomes Sporozoite rate, mosquito density, parity rate
Mosquito resistance status Olyset Net villages - resistance - high (1% mortality, N = 305)
Olyset Plus villages - resistance - high (2% mortality, N = 411)
PermaNet 2.0 villages - resistance - high (29% mortality, N = 410)
PermaNet 3.0 villages - resistance - moderate (38% mortality, N = 408)
Net treatment Nets unholed and unwashed
Location(s) Sikasso region, Mali
PermaNet 2.0 villages - Beko East, Dalabani, Berila, Dierila
PermaNet 3.0 villages - Beko West, Farabacoura East, Kola Djokada, Tieblembougou
Olyset Net villages - Karako, Geleba 2, Toula East, Toula West
Olyset Plus villages - Dialake, Farabacoura West, Deneklin, Faradjele
Notes Trial conducted: January 2014 to January 2015
Risk of bias
Bias Authors' judgement Support for judgement
Recruitment bias Low risk Recruiment bias is related to human participants and so is not applicable to
this study
Were the mosquitoes
in LLIN and LLIN + PBO
groups comparable
Unclear risk Mosquito species composition is constant between villages; however resis-
tance level varies slightly
Collectors blinded High risk Not stated whether collectors where blinded; therefore judged as high risk, as
this is likely to affect searching efforts
Household blinded Low risk Unclear whether households were blinded – not stated in the publication. We
judged this as low risk, as this is unlikely to affect the outcome
Cisse 2017 
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Low risk Villages were randomly assigned to treatment arms
Allocation concealment
(selection bias)
Low risk Allocation concealment procedures were not adhered to; however this is un-
likely to affect study results
Were incomplete out-
come data adequately ad-
dressed
Low risk No data were incomplete
Were the raw data report-
ed for LLIN and LLIN + PBO
groups
Low risk All necessary data were reported
Clusters lost to follow-up Low risk No clusters were lost to follow-up
Selective reporting (re-
porting bias)
Low risk It appears that all measured outcomes were reported
Correct statistical meth-
ods; adjusted for cluster-
ing
High risk Study did not take clustering into account for statistical methods
Trial authors' conflicting
interest





Methods Experimental hut trial
Participants Vallée du Kou, Burkina Faso - 100% An gambiae: M-form (15%), S-form (85%)
Malanville, Benin - 95% An gambiae: M-form (100%), 5% An arabiensis
Pitoa, Cameroon - 5% An gambiae: S-form (100%), 95% An arabiensis
Interventions Control: LLIN, PermaNet 2.0
Intervention: LLIN, PermaNet 3.0
Outcomes Mosquito mortality, blood feeding, deterrence, exophily
Mosquito resistance status Vallée du Kou, Burkina Faso - resistant – high (deltamethrin, 23% mortality, N = 100)
Malanville, Benin - resistant – low (deltamethrin, 85% mortality, N = 100)
Pitoa, Cameroon - resistant – low (deltamethrin, 70% mortality, N = 100)
Net treatment Nets holed, nets unwashed and washed (x 20)
Location(s) Vallée du Kou, Burkina Faso
Malanville, Benin
Corbel 2010 
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Pitoa, Cameroon
Notes Trial conducted:
Vallée du Kou, Burkina Faso - September 2007 to November 2007
Malanville, Benin - July 2008 to September 2008
Pitoa, Cameroon - July 2008 to September 2008
Risk of bias
Bias Authors' judgement Support for judgement
Were the mosquitoes
in LLIN and LLIN + PBO
groups comparable
Low risk Huts situated in the same area: mosquito characteristics will be the same
Collectors blinded Unclear risk Unclear whether collectors were blinded – not stated in the publication
Sleepers blinded Unclear risk Unclear whether sleeper was blinded – not stated in the publication




Low risk Treatments were randomly allocated to huts
Treatment rotation Low risk Treatments were rotated between huts according to a Latin square design
Standardized hut design Low risk Huts were built according to a standard West African design
Hut cleaning between
treatments
Unclear risk Unclear whether huts were cleaned between treatments – not stated in the
publication
Were incomplete out-
come data adequately ad-
dressed
Low risk No outcome data were incomplete
Were the raw data report-
ed for LLIN and LLIN + PBO
groups
Low risk All necessary data were reported
Trial authors' conflicting
interest





Methods Experimental hut trial
Participants An gambiae s.s.
Interventions Control: LLIN, PermaNet 2.0
Koudou 2011 
Piperonyl butoxide (PBO) combined with pyrethroids in insecticide-treated nets to prevent malaria in Africa (Review)










Cochrane Database of Systematic Reviews
Intervention: LLIN, PermaNet 3.0
Outcomes Mosquito mortality, deterrence, exophily
Mosquito resistance status Resistant - high (deltamethrin, 10.6% mortality, N = 80 min)
Net treatment Nets not holed, nets unwashed and washed (x 20)
Location(s) Yaokoffikro, Côte d'Ivoire
Notes Trial conducted: April 2009 to July 2009
Risk of bias
Bias Authors' judgement Support for judgement
Were the mosquitoes
in LLIN and LLIN + PBO
groups comparable
Low risk Huts situated in the same area – mosquito characteristics will be the same
Collectors blinded Unclear risk Unclear whether collectors were blinded – not stated in the publication
Sleepers blinded Unclear risk Unclear whether sleeper was blinded – not stated in the publication




Low risk Treatments were not randomly allocated to the huts
However, results from trials performed before this trial show no significant dif-
ferences in attractiveness of the different huts
Treatment rotation Low risk Treatments were rotated between huts according to a Latin square design
Standardized hut design Low risk Huts were built according to a standard West African design
Hut cleaning between
treatments
Low risk All huts were cleaned between treatments
Were incomplete out-
come data adequately ad-
dressed
Low risk No outcome data were incomplete
Were the raw data report-
ed for LLIN and LLIN + PBO
groups
Low risk All necessary data were reported
Trial authors' conflicting
interest





Methods Experimental hut trial
Moore 2016 
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Participants An arabiensis (100%), An funestus group (95% s.s.)
Interventions Control: LLIN, MAGNet LN
Intervention: LLIN, Veeralin LN
Outcomes Mosquito mortality, blood feeding, deterrence, exophily
Mosquito resistance status An arabiensis - susceptible (alpha-cypermethrin, 100% mortality, N = 97)
An funestus - unclassified
Net treatment Nets holed, nets unwashed and washed (x 20)
Location(s) Ifakara, Tanzania
Notes Although additional data provided, they show resistance to deltamethrin and permethrin in An gambi-
ae s.l.
Risk of bias
Bias Authors' judgement Support for judgement
Were the mosquitoes
in LLIN and LLIN + PBO
groups comparable
Low risk The hut trial was conducted in the same area; therefore characteristics are
similar
Collectors blinded Unclear risk Paper does not state whether collectors were blinded
Sleepers blinded Unclear risk Paper does not state whether sleepers were blinded




Low risk Treatments were not randomly allocated to huts; however the trial completed
a full rotation through the huts
Treatment rotation Low risk Treatments were rotated between huts according to a Latin square design
Standardized hut design Low risk Study used the standard design of the Ifakara experimental huts
Hut cleaning between
treatments
Unclear risk The paper does not state whether huts were cleared between treatments
Were incomplete out-
come data adequately ad-
dressed
Low risk No outcome data were incomplete
Were the raw data report-
ed for LLIN and LLIN + PBO
groups
Low risk No outcome data were missing
Trial authors' conflicting
interest
Low risk Trial authors declared they received prescribed standard fees from Vester-
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Participants An gambiae s. l., An funestus group
Interventions Control: LLIN, Olyset Net, PermaNet 2.0
Intervention: LLIN, Olyset Plus, PermaNet 3.0
Outcomes Mosquito density, parity rate
Mosquito resistance status An funestus (Balaka district)
Permethrin - resistant - moderate (55.5% mortality, N = unknown)
Deltamethrin - resistant - high (14.9% mortality, N = unknown)
An gambiae (Balaka district)
Permethrin - resistant - low (84.4% mortality, N = unknown)
(Machinga district)
Deltamethrin - resistant - moderate (54.5% mortality, N = unknown)
Net treatment Nets unholed and unwashed
Location(s) Balaka district, Malawi (12 villages)
Notes Trial conducted: December 2012 to June 2014
Risk of bias
Bias Authors' judgement Support for judgement
Recruitment bias Low risk Recruiment bias is related to human participants and so is not applicable to
this study
Were the mosquitoes
in LLIN and LLIN + PBO
groups comparable
Unclear risk Mosquito species composition and resistance status are not recorded per vil-
lage. Village names are not provided in the study; instead villages are grouped
by treatment type
Collectors blinded High risk Not stated whether collectors were blinded; therefore judged as high risk, as
this is likely to affect searching effort
Household blinded Low risk Unclear whether households were blinded – not stated in the publication. We




Low risk Villages were randomly assigned to treatment arms
Allocation concealment
(selection bias)
Low risk Allocation concealment procedures were not adhered to; however this is un-
likely to affect the results
Mzilahowa 2014 
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Were incomplete out-
come data adequately ad-
dressed
Low risk No outcome data were incomplete
Were the raw data report-
ed for LLIN and LLIN + PBO
groups
Low risk All necessary data were reported
Clusters lost to follow-up Low risk No clusters were lost to follow-up
Selective reporting (re-
porting bias)
Low risk It appears that all measured outcomes were reported
Correct statistical meth-
ods; adjusted for cluster-
ing









Methods Experimental hut trial
Participants An gambiae
Interventions Control: LLIN, PermaNet 2.0
Intervention: LLIN, PermaNet 3.0
Outcomes Mosquito mortality, blood feeding, deterrence, exophily
Mosquito resistance status Proxy data. Adjara, Benin: resistant - moderate (deltamethrin, 50% mortality, N = 56) (Aïzoun 2013)
Net treatment Nets holed, nets unwashed and washed (x 20)
Location(s) Akron, Benin
Notes Trial conducted: October 2008 to January 2009
Risk of bias
Bias Authors' judgement Support for judgement
Were the mosquitoes
in LLIN and LLIN + PBO
groups comparable
Low risk Huts were situated in the same area – mosquito characteristics will be the
same
Collectors blinded Unclear risk Unclear whether collectors were blinded – not stated in the publication
Sleepers blinded Unclear risk Unclear whether sleeper was blinded – not stated in the publication
Sleeper bias Low risk Sleepers were rotated between huts according to a Latin square design
N'Guessan 2010 
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Low risk Treatments were randomly allocated to huts
Treatment rotation Low risk Treatments were rotated between huts according to a Latin square design
Standardized hut design Low risk Huts were built according to a standard West African design
Hut cleaning between
treatments
Low risk All huts were cleaned between treatments
Were incomplete out-
come data adequately ad-
dressed
Low risk No outcome data were incomplete
Were the raw data report-
ed for LLIN and LLIN + PBO
groups
Low risk All necessary data were reported
Trial authors' conflicting
interest
Unclear risk The trial was sponsored by Vestergaard (net manufacturers), which also com-





Methods Experimental hut trial
Participants 95% An gambiae: M-form (100%), 5% An arabiensis (Corbel 2010)
Interventions Control: LLIN, Olyset Net
Intervention: LLIN, Olyset Plus
Outcomes Mosquito mortality, blood feeding, deterrence, exophily
Mosquito resistance status Proxy data. Resistant - high (permethrin, 22% mortality, N = 100) (Djègbè 2011)
Net treatment Nets holed, nets unwashed and washed (x 20)
Location(s) Malanville, Benin
Notes Trial conducted: September 2011 to December 2011
Risk of bias
Bias Authors' judgement Support for judgement
Were the mosquitoes
in LLIN and LLIN + PBO
groups comparable
Low risk Huts situated in the same area – mosquito characteristics will be the same
Collectors blinded Unclear risk Unclear whether collectors were blinded – not stated in the publication
Sleepers blinded Unclear risk Unclear whether sleeper was blinded – not stated in the publication
Pennetier 2013 
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Low risk Treatments were not randomized to huts but instead were rotated fully be-
tween all huts according to a Latin square design
Treatment rotation Low risk Treatments were rotated between huts according to a Latin square design
Standardized hut design Low risk Huts were built according to a standard West African design
Hut cleaning between
treatments
Low risk All huts were cleaned between treatments
Were incomplete out-
come data adequately ad-
dressed
Low risk No outcome data were incomplete
Were the raw data report-
ed for LLIN and LLIN + PBO
groups
Low risk All necessary data were reported
Trial authors' conflicting
interest
Low risk Funders of the trial stated that they had no part in data collection, data analy-





Methods Cluster-randomized controlled village trial
Participants 3966 children analysed (21 months after intervention) aged 6 months to 14 years (excluding the severe-
ly ill), Anopheles species (pooled). Total core cluster population ranged from 14,845 to 16,358
Interventions Control: LLIN, Olyset Net
Intervention: LLIN, Olyset Plus
Outcomes Malaria parasite prevalence, sporozoite rate, mosquito density
Mosquito resistance status Resistance - high (17.8% mortality, N = 107)
Net treatment Nets unholed and unwashed
Location(s) Muleba District, Tanzania
Notes Trial conducted: March 2014 to December 2016
Risk of bias
Bias Authors' judgement Support for judgement
Recruitment bias Low risk No participants were recruited after clusters had been randomized
Protopopo< 2018 
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Were the mosquitoes
in LLIN and LLIN + PBO
groups comparable
Unclear risk Resistance level was available only for the whole district - not at the village lev-
el
Collectors blinded Low risk Field workers were masked to net treatment




Low risk Restricted randomization was used to allocate clusters to study groups
Allocation concealment
(selection bias)
Low risk Restricted randomization was used to allocate treatments to clusters
Were incomplete out-
come data adequately ad-
dressed
Low risk No outcome data were incomplete
Were the raw data report-
ed for LLIN and LLIN + PBO
groups
Low risk No outcome data were missing
Clusters lost to follow-up Low risk No clusters were lost to follow-up
Selective reporting (re-
porting bias)
Low risk It appears that all measured outcomes were reported
Correct statistical meth-
ods; adjusted for cluster-
ing











Interventions Control: LLIN, PermaNet 2.0
Intervention: LLIN, PermaNet 3.0
Outcomes Sporozoite rate, mosquito density, parity rate
Mosquito resistance status Futa - resistant - moderate (33.3% mortality, N = 96)
Abrabra- resistant - moderate (43.7% mortality, N = 126)
Kunkumso - resistant - high (28.4% mortality, N = 109)
Anyinabrim - resistant - moderate (53.2% mortality, N = 109)
Wenchi - resistant - low (61.9% mortality, N =126)
Stiles-Ocran 2013 
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Net treatment Nets unholed and unwashed
Location(s) Futa, Ghana - no net control
Abrabra, Ghana - PermaNet 2.0
Kunkumso, Ghana - PermaNet 2.0
Anyinabrim, Ghana - PermaNet 3.0
Wench, Ghana - PermaNet 3.0
Notes Trial conducted: November 2010 to August 2011
Risk of bias
Bias Authors' judgement Support for judgement
Recruitment bias Low risk Recruiment bias is related to human participants and so is not applicable to
this study
Were the mosquitoes
in LLIN and LLIN + PBO
groups comparable
Unclear risk Mosquito species composition varied slightly. Resistance level varies between
villages. However, pre-trial and post-trial data are provided
Collectors blinded High risk Not stated whether collectors were blinded; therefore judged as high risk, as
this is likely to affect searching efforts
Household blinded Low risk Unclear whether households were blinded – not stated in the publication. We




Low risk Villages were randomly assigned to treatment arms
Allocation concealment
(selection bias)
Low risk Allocation concealment procedures were not adhered to; however this is un-
likely to affect the results
Were incomplete out-
come data adequately ad-
dressed
Low risk No outcome data were incomplete
Were the raw data report-
ed for LLIN and LLIN + PBO
groups
Low risk All necessary data were reported
Clusters lost to follow-up Low risk No clusters were lost to follow-up
Selective reporting (re-
porting bias)
Low risk It appears that all measured outcomes were reported
Correct statistical meth-
ods; adjusted for cluster-
ing
High risk Study did not take clustering into account for statistical methods
Trial authors' conflicting
interest
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Study characteristics
Methods Experimental hut trial
Participants An coluzzii
Interventions Control: LLIN, PermaNet 2.0, Olyset Net
Intervention: LLIN, PermaNet 3.0, Olyset Plus
Outcomes Mosquito mortality, blood feeding, deterrence, exophily
Mosquito resistance status Vallée du Kou 5 - resistant – high (deltamethrin, 2.5% mortality, N = 163; permethrin, 5% mortality, N =
153)
Tengrela - resistant – high (deltamethrin, 34% mortality, N = 85; permethrin, 14% mortality, N = 101)
Net treatment Nets holed, nets unwashed
Location(s) Vallée du Kou 5, Burkina Faso
Tengrela, Burkina Faso
Notes Trial conducted: September 2014 to October 2014
Risk of bias
Bias Authors' judgement Support for judgement
Were the mosquitoes
in LLIN and LLIN + PBO
groups comparable
Low risk Huts situated in the same area – mosquito characteristics will be the same
Collectors blinded Unclear risk Unclear whether collectors were blinded – not stated in the publication
Sleepers blinded Unclear risk Unclear whether sleeper was blinded – not stated in the publication




Low risk Treatments were not randomized to huts but instead were rotated fully be-
tween all huts according to a Latin square design
Treatment rotation Low risk Treatments were rotated between huts according to a Latin square design
Standardized hut design Low risk Huts were built according to a standard West African design
Hut cleaning between
treatments
Unclear risk Unclear whether huts were cleaned between treatments – not stated in the
publication
Were incomplete out-
come data adequately ad-
dressed
Low risk No outcome data were incomplete
Were the raw data report-
ed for LLIN and LLIN + PBO
groups
Low risk All necessary data were reported
Toé 2018 
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Trial authors' conflicting
interest





Methods Experimental hut trial
Participants An gambiae
Interventions Control: LLIN, PermaNet 2.0
Intervention: LLIN, PermaNet 3.0
Outcomes Mosquito mortality, blood feeding, deterrence, exophily
Mosquito resistance status Susceptible (deltamethrin, 100% mortality, N = not stated)
Net treatment Nets holed, nets unwashed and washed (x 20)
Location(s) Zeneti, Muheza, Tanzania
Notes Trial conducted: July 2008 to October 2008
Risk of bias
Bias Authors' judgement Support for judgement
Were the mosquitoes
in LLIN and LLIN + PBO
groups comparable
Low risk Huts situated in the same area – mosquito characteristics will be the same
Collectors blinded Unclear risk Unclear whether collectors were blinded – not stated in the publication
Sleepers blinded Unclear risk Unclear whether sleeper was blinded – not stated in the publication




Low risk Treatments were randomly allocated to huts
Treatment rotation Low risk Treatments were rotated between huts according to a Latin square design
Standardized hut design Low risk Huts were built according to a standard West African design
Hut cleaning between
treatments
Low risk All huts were cleaned between treatments
Were incomplete out-
come data adequately ad-
dressed
Low risk No outcome data were incomplete
Tungu 2010 
Piperonyl butoxide (PBO) combined with pyrethroids in insecticide-treated nets to prevent malaria in Africa (Review)










Cochrane Database of Systematic Reviews
Were the raw data report-
ed for LLIN and LLIN + PBO
groups
Low risk All necessary data were reported
Trial authors' conflicting
interest





Methods Experimental hut trial
Participants An funestus
Interventions Control: LLIN, PermaNet 2.0, Olyset Net
Intervention: LLIN, PermaNet 3.0, Olyset Plus
Outcomes Mosquito mortality, blood feeding, exophily
Mosquito resistance status Moderate




Bias Authors' judgement Support for judgement
Were the mosquitoes
in LLIN and LLIN + PBO
groups comparable
Low risk Huts situated in the same area – mosquito characteristics will be the same
Collectors blinded Unclear risk Unclear whether collectors were blinded – not stated in the publication
Sleepers blinded Unclear risk Unclear whether collectors were blinded – not stated in the publication




Low risk Treatments were not randomized to huts but instead were rotated fully be-
tween all huts according to a Latin square design
Treatment rotation Low risk Treatments were rotated between huts according to a Latin square design
Standardized hut design Low risk Huts were built according to a standard West African design
Hut cleaning between
treatments
Low risk All huts were cleaned between treatments
Menze 2020 
Piperonyl butoxide (PBO) combined with pyrethroids in insecticide-treated nets to prevent malaria in Africa (Review)










Cochrane Database of Systematic Reviews
Were incomplete out-
come data adequately ad-
dressed
Low risk No outcome data were incomplete
Were the raw data report-
ed for LLIN and LLIN + PBO
groups
Low risk No outcome data were missing
Correct statistical meth-
ods; adjusted for cluster-
ing
Low risk Clustering was not taken into account and adjusted for during statistical
analysis. We adjusted for clustering by using an ICC value of 0.1
Trial authors' conflicting
interest





Methods Experimental hut trial
Participants An gambiae
Interventions Control: LLIN, MAGNet LN
Intervention: LLIN, Veeralin LN
Outcomes Mosquito mortality, blood feeding, deterrence, exophily
Mosquito resistance status Low resistance
Net treatment Nets holed, nets unwashed and washed (x 20)
Location(s) M'be Côte d'Ivoire
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Were the mosquitoes
in LLIN and LLIN + PBO
groups comparable
Low risk Huts situated in the same area – mosquito characteristics will be the same
Collectors blinded Unclear risk Unclear whether collectors were blinded – not stated in the publication
Sleepers blinded Unclear risk Unclear whether collectors were blinded – not stated in the publication




Low risk Treatments were randomly allocated to huts
Oumbouke 2019 
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Treatment rotation Low risk Treatment were rotated between huts according to a Latin Square design
Standardized hut design Low risk Huts were built previously according to standard West African hut design
Hut cleaning between
treatments
Low risk Huts were thoroughly cleaned and aired for a day at the end of each rotation
Were incomplete out-
come data adequately ad-
dressed
Low risk No outcome data were incomplete
Were the raw data report-
ed for LLIN and LLIN + PBO
groups
Low risk No outcome data were missing
Correct statistical meth-
ods; adjusted for cluster-
ing
Low risk Clustering was not taken into account and adjusted for during statistical
analysis. We adjusted for clustering using an ICC value of 0.1
Trial authors' conflicting
interest
Low risk Trial authors state that they have no conflicting interests
Oumbouke 2019  (Continued)
An arabiensis: Anopheles arabiensis; An coluzzii: Anopheles coluzzii; An funestus: Anopheles funestus; An gambiae: Anopheles gambiae; ITN:
insecticide-treated net; LLIN: long-lasting insecticidal net; PBO: piperonyl butoxide.
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Darriet 2011 Study included laboratory data only
Darriet 2013 Study included laboratory data only
 
Characteristics of studies awaiting classification [ordered by study ID]
 
Methods Village trial
Participants Bouaké - 100% An gambiae: (70% S-form, 30% M-form)
Tiassalé - 100% An gambiae: (70% S-form, 30% M-form)
Interventions Control: LLIN, PermaNet 2.0 Extra
Intervention: LLIN, PermaNet 3.0
Outcomes Blood feeding, mosquito density
Mosquito Resistance Status Bouaké - resistant - moderate (43.9% mortality, N = 114)
Tiassalé - resistant - moderate (7.5% mortality, N = 106)
Net Treatment Nets unholed and unwashed
Location(s) Bouaké, Côte d’Ivoire
Koudou 2012 
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Tiassalé, Côte d’Ivoire





Participants An funestus: Anopheles funestus; An gambiae: Anopheles gambiae
Interventions  
Outcomes Not available
Mosquito Resistance Status Not available
Net Treatment Control: LLIN, Olyset Net






Methods Experimental hut trial
Participants An funestus
Interventions Control: LLIN, DawaPlus 2.0
Intervention: LLIN, DawaPlus 3.0, DawaPlus 4.0
Outcomes Mosquito mortality, blood feeding, deterrence, exophily
Mosquito Resistance Status  





Characteristics of ongoing studies [ordered by study ID]
 
Study name Comparative evaluation of standard insecticide-treated bed nets and co-treated bed nets on
malaria prevalence in Sud Ubangi, Democratic Republic of Congo: a cluster-randomised trial
ISRCTN99611164 
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Methods Cluster-randomized trial
Participants Women (> 15 years) attending first ANC appointment at a clinic that is taking part in the study, who
consent to be enrolled in the study
20 visitors per month at each of 7 antenatal clinics (held monthly) in each of 17 study clusters,
which gives a total of approximately 2400 participants per month, 28,500 per year, and 86,000 in to-
tal
Interventions Control: bed net treated with pyrethroid only
Intervention: bed net treated with both pyrethroid and PBO
Outcomes 1. Determination of parasite prevalence in women visiting monthly antenatal clinics
2. Entomological collections for surveillance of insecticide resistance and mosquito abundance
and parasite infection
3. Assessment of bed net durability (physical and chemical analysis) and bio-efficacy (against mos-
quitoes) over time
Starting date November 2019 (recruitment start date 01/06/2020)





Study name Effectiveness study of new-generation bed nets in the context of conventional insecticide resis-
tance in the Democratic Republic of the Congo (Net-PBO)
Methods Cluster-randomized trial
Participants 1680 participants; 0 to 10-year-old subjects in 30 villages
Interventions Control: bed net treated with pyrethroid only
Intervention: bed net treated with both pyrethroid and PBO
(IRS and LSM included in trial)
Outcomes Incidence rate of laboratory-confirmed clinical cases of malaria (time frame: participants will be
actively followed up for 12 months, and any suspected case of clinical malaria will immediate-
ly lead to microscopy and RDT for confirmation). Microscopy to confirm the diagnosis of malaria
sporozoite rate (time frame: Anopheles mosquitoes will be captured every 3 months during 1 year),
sporozoite detection by ELISA to determine infectivity of Anopheles
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Study name HS#2017-3512. Adaptive interventions for optimizing malaria control: a cluster-randomized SMART
trial
Methods Cluster-randomized trial
Participants 122,872 participants (6 months and older, all sexes)
Interventions Other: regular long-lasting insecticidal nets (Olyset)
Other: LLIN plus piperonyl butoxide-treated LLIN (Olyset Plus)










Study name A preliminary study on designing a cluster randomized control trial of two mosquito nets to pre-
vent malaria parasite infection
Methods Cluster-randomized trial
Participants 1360 target participants
Children targeted for malaria transmission survey are aged between 7 and 131 months
Children between 60 and 131 months old are schoolchildren; 170 children are randomly selected
from each cluster for survey
Interventions Control: bed net treated with pyrethroid only
Intervention: bed net treated with both pyrethroid and PBO





Contact information Dr Noboru Minakawa
Notes  
UMIN000019971 
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ELISA: enzyme-linked immunosorbent assay; PBO: piperonyl butoxide.
 
 
D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Commercial pyrethroid-PBO nets versus commercial LLINs: village trials
Outcome or subgroup title No. of studies No. of partici-
pants
Statistical method Effect size
1.1 Parasite prevalence (pyrethroid-
PBO nets vs non-PBO LLINs, latest end
points in RCT)
2   Odds Ratio (IV, Fixed, 95%
CI)
0.79 [0.67, 0.95]
1.2 Parasite prevalence (pyrethroid-
PBO nets vs non-PBO LLINs, shown at 4
different time points)
2   Odds Ratio (IV, Fixed, 95%
CI)
Subtotals only
1.2.1 4 to 6 months 2   Odds Ratio (IV, Fixed, 95%
CI)
0.74 [0.62, 0.89]
1.2.2 9 to 12 months 2   Odds Ratio (IV, Fixed, 95%
CI)
0.72 [0.61, 0.86]
1.2.3 16 to 18 months 2   Odds Ratio (IV, Fixed, 95%
CI)
0.88 [0.74, 1.04]
1.2.4 21 to 25 months 2   Odds Ratio (IV, Fixed, 95%
CI)
0.79 [0.67, 0.95]
1.3 Mosquito sporozoite-positive (ad-
justed ICC 0.1)
4 424 Risk Ratio (M-H, Random,
95% CI)
0.82 [0.24, 2.75]
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Analysis 1.1.   Comparison 1: Commercial pyrethroid-PBO nets versus commercial LLINs: village trials,





Heterogeneity: Chi² = 4.03, df = 1 (P = 0.04); I² = 75%
Test for overall effect: Z = 2.57 (P = 0.01)












IV, Fixed, 95% CI
0.40 [0.20 , 0.80]
0.83 [0.70 , 1.00]
0.79 [0.67 , 0.95]
Odds Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours Pyrethroid-PBO Favours LLINs
Footnotes
(1) 21 months after intervention
(2) 25 months after intervention
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Analysis 1.2.   Comparison 1: Commercial pyrethroid-PBO nets versus commercial LLINs: village trials,
Outcome 2: Parasite prevalence (pyrethroid-PBO nets vs non-PBO LLINs, shown at 4 di<erent time points)
Study or Subgroup




Heterogeneity: Chi² = 0.11, df = 1 (P = 0.74); I² = 0%
Test for overall effect: Z = 3.27 (P = 0.001)




Heterogeneity: Chi² = 5.95, df = 1 (P = 0.01); I² = 83%
Test for overall effect: Z = 3.60 (P = 0.0003)




Heterogeneity: Chi² = 4.68, df = 1 (P = 0.03); I² = 79%
Test for overall effect: Z = 1.47 (P = 0.14)




Heterogeneity: Chi² = 4.03, df = 1 (P = 0.04); I² = 75%

































IV, Fixed, 95% CI
0.68 [0.39 , 1.19]
0.75 [0.62 , 0.91]
0.74 [0.62 , 0.89]
0.37 [0.21 , 0.65]
0.78 [0.65 , 0.94]
0.72 [0.61 , 0.86]
0.47 [0.26 , 0.85]
0.93 [0.78 , 1.12]
0.88 [0.74 , 1.04]
0.40 [0.20 , 0.80]
0.83 [0.70 , 1.00]
0.79 [0.67 , 0.95]
Odds Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours Pyrethroid-PBO Favours LLINsFootnotes
(1) 4 months after intervention
(2) 6 months after intervention
(3) 9 months after intervention
(4) 12 months after intervention
(5) 16 months after intervention
(6) 18 months after intervention
(7) 21 months after intervention
(8) 25 months after intervention
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Analysis 1.3.   Comparison 1: Commercial pyrethroid-PBO nets versus commercial









Heterogeneity: Tau² = 0.00; Chi² = 1.46, df = 2 (P = 0.48); I² = 0%
Test for overall effect: Z = 0.33 (P = 0.74)





































M-H, Random, 95% CI
Not estimable
0.81 [0.05 , 12.55]
1.58 [0.28 , 8.94]
0.29 [0.03 , 2.53]
Not estimable
0.82 [0.24 , 2.75]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours Pyrethroid PBO Favours LLINs
Footnotes
(1) Permanet 3.0, Low resistance
(2) Permanet 3.0, Moderate resistance
(3) Olyset Plus, High resistance
 
 
Analysis 1.4.   Comparison 1: Commercial pyrethroid-PBO nets versus








Heterogeneity: Tau² = 0.00; Chi² = 0.01, df = 3 (P = 1.00); I² = 0%
Test for overall effect: Z = 0.43 (P = 0.66)


































M-H, Random, 95% CI
0.97 [0.76 , 1.24]
0.96 [0.75 , 1.22]
0.97 [0.58 , 1.64]
0.98 [0.49 , 1.97]
0.97 [0.82 , 1.13]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours Pyrethroid-PBO Favours LLIN
Footnotes
(1) Olyset Plus, High resistance
(2) Permanet 3.0, Moderate resistance
(3) Permanet 3.0, Anopheles funestus
 
 
Comparison 2.   Commercial pyrethroid-PBO nets versus commercial LLINs: hut trials
Outcome or subgroup title No. of studies No. of partici-
pants
Statistical method Effect size
2.1 Mosquito mortality (pooled)
hut/night (adjusted ICC 0.1)
10 15614 Risk Ratio (M-H, Random, 95%
CI)
1.43 [1.26, 1.62]
2.1.1 Unwashed 10 8647 Risk Ratio (M-H, Random, 95%
CI)
1.63 [1.29, 2.05]
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Outcome or subgroup title No. of studies No. of partici-
pants
Statistical method Effect size
2.1.2 Washed 8 6967 Risk Ratio (M-H, Random, 95%
CI)
1.19 [1.04, 1.38]
2.2 Mosquito blood-feeding suc-
cess (pooled) hut/night (adjusted
ICC 0.1)
9 12351 Risk Ratio (M-H, Random, 95%
CI)
0.75 [0.66, 0.85]
2.2.1 Unwashed 9 7261 Risk Ratio (M-H, Random, 95%
CI)
0.68 [0.57, 0.80]
2.2.2 Washed 7 5090 Risk Ratio (M-H, Random, 95%
CI)
0.87 [0.74, 1.02]
2.3 Mosquito exophily (pooled)
hut/night (adjusted ICC 0.1)
10 13214 Risk Ratio (M-H, Random, 95%
CI)
1.00 [0.94, 1.06]
2.3.1 Unwashed 10 7699 Risk Ratio (M-H, Random, 95%
CI)
1.00 [0.91, 1.10]
2.3.2 Washed 8 5515 Risk Ratio (M-H, Random, 95%
CI)
1.00 [0.93, 1.07]
2.4 Mosquito mortality (high re-
sistance) hut/night (adjusted ICC
0.1)
5 7997 Risk Ratio (M-H, Random, 95%
CI)
1.58 [1.34, 1.86]
2.4.1 Unwashed 5 4896 Risk Ratio (M-H, Random, 95%
CI)
1.84 [1.60, 2.11]
2.4.2 Washed 4 3101 Risk Ratio (M-H, Random, 95%
CI)
1.20 [0.88, 1.63]
2.5 Mosquito blood-feeding suc-
cess (high resistance) hut/night
(adjusted ICC 0.1)
4 7134 Risk Ratio (M-H, Random, 95%
CI)
0.66 [0.57, 0.76]
2.5.1 Unwashed 4 4458 Risk Ratio (M-H, Random, 95%
CI)
0.60 [0.50, 0.71]
2.5.2 Washed 3 2676 Risk Ratio (M-H, Random, 95%
CI)
0.81 [0.72, 0.92]
2.6 Mosquito mortality (moder-
ate resistance) hut/night (adjust-
ed ICC 0.1)
2 1027 Risk Ratio (M-H, Fixed, 95% CI) 1.47 [1.21, 1.78]
2.6.1 Unwashed 2 751 Risk Ratio (M-H, Fixed, 95% CI) 1.68 [1.33, 2.11]
2.6.2 Washed 1 276 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.74, 1.54]
2.7 Mosquito blood-feeding suc-
cess (moderate resistance) hut/
night (adjusted ICC 0.1)
2 1034 Risk Ratio (M-H, Random, 95%
CI)
0.91 [0.78, 1.05]
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Outcome or subgroup title No. of studies No. of partici-
pants
Statistical method Effect size
2.7.1 Unwashed 2 752 Risk Ratio (M-H, Random, 95%
CI)
0.90 [0.72, 1.11]
2.7.2 Washed 1 282 Risk Ratio (M-H, Random, 95%
CI)
0.91 [0.74, 1.13]
2.8 Mosquito mortality (low re-
sistance) hut/night (adjusted ICC
0.1)
2 1970 Risk Ratio (M-H, Random, 95%
CI)
1.30 [1.09, 1.56]
2.8.1 Unwashed 2 948 Risk Ratio (M-H, Random, 95%
CI)
1.25 [0.99, 1.57]
2.8.2 Washed 2 1022 Risk Ratio (M-H, Random, 95%
CI)
1.39 [0.95, 2.04]
2.9 Mosquito blood-feeding suc-
cess (low resistance) hut/night
(adjusted ICC 0.1)
2 1970 Risk Ratio (M-H, Random, 95%
CI)
0.94 [0.56, 1.57]
2.9.1 Unwashed 2 948 Risk Ratio (M-H, Random, 95%
CI)
0.75 [0.27, 2.11]
2.9.2 Washed 2 1022 Risk Ratio (M-H, Random, 95%
CI)
1.07 [0.49, 2.33]
2.10 Mosquito mortality (suscep-
tible) hut/night (adjusted ICC 0.1)
2 1916 Risk Ratio (M-H, Random, 95%
CI)
1.05 [0.96, 1.15]
2.10.1 Unwashed 2 948 Risk Ratio (M-H, Random, 95%
CI)
1.20 [0.64, 2.26]
2.10.2 Washed 2 968 Risk Ratio (M-H, Random, 95%
CI)
1.07 [0.92, 1.25]
2.11 Mosquito blood-feeding suc-
cess (susceptible) hut/night (ad-
justed ICC 0.1)
2 1916 Risk Ratio (M-H, Random, 95%
CI)
0.87 [0.40, 1.89]
2.11.1 Unwashed 2 948 Risk Ratio (M-H, Random, 95%
CI)
0.52 [0.12, 2.22]
2.11.2 Washed 2 968 Risk Ratio (M-H, Random, 95%
CI)
1.25 [0.82, 1.91]
2.12 Mosquito mortality (high re-
sistance/Permanet) hut/night
(adjusted ICC 0.1)
3 2806 Risk Ratio (M-H, Random, 95%
CI)
1.59 [1.26, 2.01]
2.12.1 Not Washed 3 1877 Risk Ratio (M-H, Random, 95%
CI)
1.81 [1.56, 2.10]
2.12.2 Washed 2 929 Risk Ratio (M-H, Random, 95%
CI)
1.18 [0.61, 2.28]
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Outcome or subgroup title No. of studies No. of partici-
pants
Statistical method Effect size
2.13 Mosquito blood-feeding suc-
cess (high resistance/Permanet)
hut/night (adjusted ICC 0.1)
2 1943 Risk Ratio (M-H, Random, 95%
CI)
0.58 [0.45, 0.76]
2.13.1 Unwashed 2 1439 Risk Ratio (M-H, Random, 95%
CI)
0.53 [0.40, 0.69]
2.13.2 Washed 1 504 Risk Ratio (M-H, Random, 95%
CI)
0.76 [0.61, 0.93]
2.14 Mosquito mortality (high re-
sistance/Olyset) hut/night (ad-
justed ICC 0.1)
2 1410 Risk Ratio (M-H, Random, 95%
CI)
1.73 [1.51, 1.97]
2.14.1 Unwashed 2 1257 Risk Ratio (M-H, Random, 95%
CI)
1.72 [1.48, 1.99]
2.14.2 Washed 1 153 Risk Ratio (M-H, Random, 95%
CI)
1.81 [1.25, 2.61]
2.15 Mosquito blood-feeding suc-
cess (high resistance/Olyset) hut/
night (adjusted ICC 0.1)
2 1470 Risk Ratio (M-H, Random, 95%
CI)
0.63 [0.40, 0.98]
2.15.1 Unwashed 2 1257 Risk Ratio (M-H, Random, 95%
CI)
0.67 [0.38, 1.18]
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Analysis 2.1.   Comparison 2: Commercial pyrethroid-PBO nets versus commercial LLINs: hut trials, Outcome 1:























Heterogeneity: Tau² = 0.22; Chi² = 750.61, df = 17 (P < 0.00001); I² = 98%
















Heterogeneity: Tau² = 0.04; Chi² = 63.76, df = 11 (P < 0.00001); I² = 83%
Test for overall effect: Z = 2.46 (P = 0.01)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.10; Chi² = 615.89, df = 29 (P < 0.00001); I² = 95%
Test for overall effect: Z = 5.56 (P < 0.00001)














































































































































































M-H, Random, 95% CI
2.89 [2.38 , 3.50]
1.45 [1.16 , 1.81]
1.13 [1.01 , 1.25]
1.09 [1.03 , 1.16]
1.76 [1.47 , 2.12]
1.57 [1.26 , 1.95]
2.51 [1.36 , 4.63]
2.61 [1.56 , 4.35]
1.07 [0.34 , 3.35]
1.55 [0.90 , 2.69]
1.16 [0.88 , 1.54]
1.76 [1.35 , 2.28]
1.96 [1.49 , 2.56]
1.44 [1.05 , 1.97]
1.72 [1.41 , 2.09]
2.41 [1.83 , 3.18]
1.76 [1.47 , 2.11]
1.00 [0.97 , 1.04]
1.63 [1.29 , 2.05]
1.05 [0.85 , 1.30]
0.92 [0.73 , 1.16]
0.99 [0.85 , 1.16]
1.63 [1.36 , 1.96]
1.39 [1.18 , 1.63]
0.84 [0.65 , 1.09]
0.87 [0.52 , 1.46]
0.81 [0.24 , 2.74]
1.07 [0.74 , 1.54]
2.17 [1.53 , 3.08]
1.81 [1.38 , 2.39]
1.09 [1.04 , 1.15]
1.19 [1.04 , 1.38]
1.43 [1.26 , 1.62]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours LLINs Favours PBO-LLINs
Footnotes
(1) Valle du Kou, DawaPlus 4.0, High resistance
(2) Valle du Kou, DawaPlus 3.0, High resistance
(3) Pitoa, Permanet 3.0, Low resistance
(4) Malanville, Permanet 3.0, Low resistance
(5) Vallée du Kou, Permanet 3.0, High resistance
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Analysis 2.1.   (Continued)
(4) Malanville, Permanet 3.0, Low resistance
(5) Vallée du Kou, Permanet 3.0, High resistance
(6) Yaokoffikro, Permanet 3.0, High resistance
(7) Mibellon, Olyset Plus, Moderate resistance, An funestus
(8) Mibellon, PermaNet 3.0, moderate resistance, An funestus
(9) Ifakara, Veeralin, Unclassified, An funestus
(10) Ifakara, Veeralin, Susceptible, An arabiensis
(11) Akron, Permanet 3.0, Moderate resistance
(12) Cote d'Ivoire, VEERALIN, Low resistance
(13) Malanaville, Olyset Plus, High resistance
(14) Tengrela, Olyset Plus, High resistance
(15) Vallee du Kou 5, Olyset Plus, High resistance
(16) Tengrela, Permanet 3.0, High resistance
(17) Vallee du Kou 5, Permanet 3.0, High resistance
(18) Zeneti, Permanet 3.0, Susceptible
(19) Ifakara, Veeralin, Susceptible, An arabiensis
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Analysis 2.2.   Comparison 2: Commercial pyrethroid-PBO nets versus commercial LLINs: hut trials, Outcome 2:






















Heterogeneity: Tau² = 0.06; Chi² = 53.70, df = 16 (P < 0.00001); I² = 70%















Heterogeneity: Tau² = 0.03; Chi² = 28.71, df = 10 (P = 0.001); I² = 65%
Test for overall effect: Z = 1.73 (P = 0.08)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.06; Chi² = 103.45, df = 27 (P < 0.00001); I² = 74%
Test for overall effect: Z = 4.48 (P < 0.00001)




































































































































































M-H, Random, 95% CI
0.56 [0.47 , 0.67]
0.71 [0.62 , 0.81]
1.82 [1.02 , 3.25]
0.59 [0.42 , 0.82]
0.16 [0.02 , 1.31]
1.12 [0.64 , 1.94]
0.83 [0.48 , 1.41]
1.28 [0.33 , 4.93]
1.11 [0.39 , 3.15]
0.87 [0.67 , 1.13]
0.58 [0.42 , 0.80]
0.92 [0.37 , 2.24]
0.60 [0.47 , 0.78]
0.38 [0.26 , 0.56]
0.87 [0.67 , 1.14]
0.43 [0.29 , 0.62]
0.25 [0.11 , 0.60]
0.68 [0.57 , 0.80]
0.90 [0.79 , 1.03]
0.80 [0.70 , 0.93]
0.76 [0.61 , 0.93]
1.23 [0.80 , 1.90]
2.13 [1.05 , 4.34]
1.73 [0.73 , 4.08]
0.11 [0.01 , 1.95]
0.92 [0.75 , 1.14]
0.54 [0.39 , 0.74]
0.50 [0.27 , 0.93]
1.12 [0.69 , 1.83]
0.87 [0.74 , 1.02]
0.75 [0.66 , 0.85]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours PBO-LLINs Favours LLINs
Footnotes
(1) Vallee du Kou, DawaPlus 4.0, High resistance
(2) Vallee du Kou, DawaPlus 3.0, High resistance
(3) Pitoa, Permanet 3.0, Low resistance
(4) Vallée du Kou, Permanet 3.0, High resistance
(5) Malanville, Permanet 3.0, Low resistance
(6) Mibellon, Olyset Plus, Moderate resistance, An funestus
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Analysis 2.2.   (Continued)
(4) Vallée du Kou, Permanet 3.0, High resistance
(5) Malanville, Permanet 3.0, Low resistance
(6) Mibellon, Olyset Plus, Moderate resistance, An funestus
(7) Mibellon, PermaNet 3.0, moderate resistance, An funestus
(8) Ifakara, Veeralin, Unclassified, An funestus
(9) Ifakara, Veeralin, Susceptible, An arabiensis
(10) Akron, Permanet 3.0, Moderate resistance
(11) Cote d'Ivoire, VEERALIN, Low resistance
(12) Tengrela, Permanet 3.0, High resistance
(13) Vallee du Kou 5, Permanet 3.0, High resistance
(14) Tengrela, Olyset Plus, High resistance
(15) Vallee du Kou 5, Olyset Plus, High resistance
(16) Zeneti, Permanet 3.0, Susceptible
(17) Malanville, Olyset Plus, High resistance
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Analysis 2.3.   Comparison 2: Commercial pyrethroid-PBO nets versus commercial LLINs: hut trials, Outcome 3:























Heterogeneity: Tau² = 0.03; Chi² = 100.21, df = 17 (P < 0.00001); I² = 83%
















Heterogeneity: Tau² = 0.01; Chi² = 32.00, df = 11 (P = 0.0008); I² = 66%
Test for overall effect: Z = 0.04 (P = 0.97)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.02; Chi² = 132.61, df = 29 (P < 0.00001); I² = 78%
Test for overall effect: Z = 0.03 (P = 0.97)














































































































































































M-H, Random, 95% CI
1.26 [1.09 , 1.46]
1.72 [1.52 , 1.96]
0.99 [0.90 , 1.09]
0.87 [0.72 , 1.04]
0.94 [0.75 , 1.18]
0.87 [0.73 , 1.03]
0.76 [0.50 , 1.15]
0.97 [0.57 , 1.65]
0.97 [0.88 , 1.07]
0.96 [0.83 , 1.12]
0.93 [0.75 , 1.15]
1.00 [0.83 , 1.20]
0.77 [0.60 , 1.00]
1.07 [0.86 , 1.35]
1.08 [0.84 , 1.40]
0.96 [0.82 , 1.11]
0.98 [0.83 , 1.16]
0.92 [0.85 , 1.00]
1.00 [0.91 , 1.10]
1.04 [0.92 , 1.19]
0.99 [0.87 , 1.13]
0.99 [0.79 , 1.25]
1.12 [1.01 , 1.25]
1.12 [0.96 , 1.32]
0.85 [0.72 , 1.01]
0.92 [0.83 , 1.02]
0.96 [0.79 , 1.15]
0.99 [0.78 , 1.25]
1.37 [1.14 , 1.65]
0.75 [0.60 , 0.94]
0.96 [0.90 , 1.03]
1.00 [0.93 , 1.07]
1.00 [0.94 , 1.06]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours PBO-LLINs Favours LLINs
Footnotes
(1) Vallee du Kou. DawaPlus 3.0, High resistance
(2) Vallee du Kou. DawaPlus 4.0, High resistance
(3) Vallée du Kou, Permanet 3.0, HIgh resistance
(4) Malanville, Permanet 3.0, Low resistance
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Analysis 2.3.   (Continued)
(2) Vallee du Kou. DawaPlus 4.0, High resistance
(3) Vallée du Kou, Permanet 3.0, HIgh resistance
(4) Malanville, Permanet 3.0, Low resistance
(5) Pitoa, Permanet 3.0, Low resistance
(6) Yaokoffikro, Permanet 3.0, High resistance
(7) Mibellon, Olyset Plus, Moderate resistance, An funestus
(8) Mibellon, PermaNet 3.0, moderate resistance, An funestus
(9) Ifakara, Veeralin, Susceptible, An arabiensis
(10) Ifakara, Veeralin, Unclassified, An funestus
(11) Akron, Permanet 3.0, Moderate resistance
(12) Malanville, Olyset Plus, High resistance
(13) Tengrela, Olyset Plus, High resistance
(14) Tengrela, Permanet 3.0, High resistance
(15) Vallee du Kou 5 ,Olyset Plus, High resistance
(16) Vallee du Kou 5, Permanet 3.0, High resistance
(17) Zeneti, Permanet 3.0, Susceptible
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Analysis 2.4.   Comparison 2: Commercial pyrethroid-PBO nets versus commercial LLINs:














Heterogeneity: Tau² = 0.03; Chi² = 25.39, df = 8 (P = 0.001); I² = 68%









Heterogeneity: Tau² = 0.11; Chi² = 27.69, df = 4 (P < 0.0001); I² = 86%
Test for overall effect: Z = 1.14 (P = 0.25)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.08; Chi² = 84.86, df = 13 (P < 0.00001); I² = 85%
Test for overall effect: Z = 5.46 (P < 0.00001)






























































































M-H, Random, 95% CI
1.45 [1.10 , 1.92]
2.87 [2.26 , 3.64]
1.76 [1.47 , 2.12]
1.57 [1.26 , 1.95]
1.96 [1.49 , 2.56]
1.72 [1.41 , 2.09]
1.76 [1.47 , 2.11]
2.41 [1.83 , 3.18]
1.44 [1.05 , 1.97]
1.84 [1.60 , 2.11]
1.05 [0.80 , 1.38]
0.93 [0.69 , 1.24]
1.64 [1.31 , 2.06]
0.84 [0.65 , 1.09]
1.81 [1.38 , 2.39]
1.20 [0.88 , 1.63]
1.58 [1.34 , 1.86]
Risk Ratio
M-H, Random, 95% CI
0.02 0.1 1 10 50
Favours LLINs Favours PBO-LLINs
Footnotes
(1) Valle du Kou, DawaPlus 3.0, High resistance
(2) Valle du Kou, DawaPlus 4.0, High resistance
(3) Vallée du Kou, Permanet 3.0, High resistance
(4) Yaokoffikro, Permanet 3.0, High resistance
(5) Malanaville, Olyset Plus, High resistance
(6) Vallee du Kou 5, Olyset Plus, High resistance
(7) Vallee du Kou 5, Permanet 3.0, High resistance
(8) Tengrela, Permanet 3.0, High resistance
(9) Tengrela, Olyset Plus, High resistance
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Analysis 2.5.   Comparison 2: Commercial pyrethroid-PBO nets versus commercial LLINs: hut













Heterogeneity: Tau² = 0.04; Chi² = 23.11, df = 7 (P = 0.002); I² = 70%








Heterogeneity: Tau² = 0.01; Chi² = 5.07, df = 3 (P = 0.17); I² = 41%
Test for overall effect: Z = 3.24 (P = 0.001)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.04; Chi² = 48.33, df = 11 (P < 0.00001); I² = 77%
Test for overall effect: Z = 5.72 (P < 0.00001)




















































































M-H, Random, 95% CI
0.56 [0.47 , 0.67]
0.71 [0.62 , 0.81]
0.59 [0.42 , 0.82]
0.92 [0.37 , 2.24]
0.38 [0.26 , 0.56]
0.87 [0.67 , 1.14]
0.43 [0.29 , 0.62]
0.60 [0.47 , 0.78]
0.60 [0.50 , 0.71]
0.80 [0.70 , 0.93]
0.90 [0.79 , 1.03]
0.76 [0.61 , 0.93]
0.50 [0.27 , 0.93]
0.81 [0.72 , 0.92]
0.66 [0.57 , 0.76]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours PBO-LLINs Favours LLINs
Footnotes
(1) Vallee du Kou, DawaPlus 4.0, High resistance
(2) Vallee du Kou, DawaPlus 3.0, High resistance
(3) Vallée du Kou, Permanet 3.0, High resistance
(4) Malanville, Olyset Plus, High resistance
(5) Vallee du Kou 5, Permanet 3.0, High resistance
(6) Tengrela, Olyset Plus, High resistance
(7) Vallee du Kou 5, Olyset Plus, High resistance
(8) Tengrela, Permanet 3.0, High resistance
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Analysis 2.6.   Comparison 2: Commercial pyrethroid-PBO nets versus commercial LLINs: hut








Heterogeneity: Chi² = 10.98, df = 2 (P = 0.004); I² = 82%






Test for overall effect: Z = 0.36 (P = 0.72)
Total (95% CI)
Total events:
Heterogeneity: Chi² = 13.31, df = 3 (P = 0.004); I² = 77%
Test for overall effect: Z = 3.86 (P = 0.0001)












































M-H, Fixed, 95% CI
2.51 [1.36 , 4.63]
2.61 [1.56 , 4.35]
1.16 [0.88 , 1.54]
1.68 [1.33 , 2.11]
1.07 [0.74 , 1.54]
1.07 [0.74 , 1.54]
1.47 [1.21 , 1.78]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours LLINs Favours PBO-LLINs
Footnotes
(1) Mibellon, Olyset Plus, Moderate resistance, An funestus
(2) Mibellon, PermaNet 3.0, moderate resistance, An funestus
(3) Akron, Permanet 3.0, Moderate resistance
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Analysis 2.7.   Comparison 2: Commercial pyrethroid-PBO nets versus commercial LLINs: hut trials,








Heterogeneity: Tau² = 0.00; Chi² = 0.77, df = 2 (P = 0.68); I² = 0%






Test for overall effect: Z = 0.84 (P = 0.40)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 0.77, df = 3 (P = 0.86); I² = 0%
Test for overall effect: Z = 1.29 (P = 0.20)












































M-H, Random, 95% CI
1.12 [0.64 , 1.94]
0.83 [0.48 , 1.41]
0.87 [0.67 , 1.13]
0.90 [0.72 , 1.11]
0.91 [0.74 , 1.13]
0.91 [0.74 , 1.13]
0.91 [0.78 , 1.05]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours PBO-LLINs Favours LLINs
Footnotes
(1) Mibellon, Olyset Plus, Moderate resistance, An funestus
(2) Mibellon, PermaNet 3.0, moderate resistance, An funestus
(3) Akron, Permanet 3.0, Moderate resistance
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Analysis 2.8.   Comparison 2: Commercial pyrethroid-PBO nets versus commercial LLINs:








Heterogeneity: Tau² = 0.03; Chi² = 23.55, df = 2 (P < 0.00001); I² = 92%







Heterogeneity: Tau² = 0.10; Chi² = 23.97, df = 2 (P < 0.00001); I² = 92%
Test for overall effect: Z = 1.70 (P = 0.09)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.04; Chi² = 53.37, df = 5 (P < 0.00001); I² = 91%
Test for overall effect: Z = 2.86 (P = 0.004)






















































M-H, Random, 95% CI
1.09 [1.03 , 1.16]
1.13 [1.01 , 1.25]
1.76 [1.35 , 2.28]
1.25 [0.99 , 1.57]
0.98 [0.86 , 1.13]
1.39 [1.18 , 1.63]
2.17 [1.53 , 3.08]
1.39 [0.95 , 2.04]
1.30 [1.09 , 1.56]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours LLINs Favours PBO-LLINs
Footnotes
(1) Malanville, Permanet 3.0, Low resistance
(2) Pitoa, Permanet 3.0, Low resistance
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Analysis 2.9.   Comparison 2: Commercial pyrethroid-PBO nets versus commercial LLINs: hut








Heterogeneity: Tau² = 0.61; Chi² = 13.59, df = 2 (P = 0.001); I² = 85%







Heterogeneity: Tau² = 0.40; Chi² = 16.87, df = 2 (P = 0.0002); I² = 88%
Test for overall effect: Z = 0.18 (P = 0.86)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.30; Chi² = 30.72, df = 5 (P < 0.0001); I² = 84%
Test for overall effect: Z = 0.24 (P = 0.81)






















































M-H, Random, 95% CI
0.16 [0.02 , 1.31]
1.82 [1.02 , 3.25]
0.58 [0.42 , 0.80]
0.75 [0.27 , 2.11]
2.13 [1.05 , 4.34]
1.23 [0.80 , 1.90]
0.54 [0.39 , 0.74]
1.07 [0.49 , 2.33]
0.94 [0.56 , 1.57]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours PBO-LLINs Favours LLINs
Footnotes
(1) Malanville, Permanet 3.0, Low resistance
(2) Pitoa, Permanet 3.0, Low resistance
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Analysis 2.10.   Comparison 2: Commercial pyrethroid-PBO nets versus commercial LLINs:







Heterogeneity: Tau² = 0.18; Chi² = 5.47, df = 1 (P = 0.02); I² = 82%






Heterogeneity: Tau² = 0.01; Chi² = 1.16, df = 1 (P = 0.28); I² = 14%
Test for overall effect: Z = 0.93 (P = 0.35)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 11.29, df = 3 (P = 0.01); I² = 73%
Test for overall effect: Z = 1.08 (P = 0.28)












































M-H, Random, 95% CI
1.55 [0.90 , 2.69]
1.00 [0.97 , 1.04]
1.20 [0.64 , 2.26]
0.87 [0.52 , 1.46]
1.09 [1.04 , 1.15]
1.07 [0.92 , 1.25]
1.05 [0.96 , 1.15]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours LLINs Favours PBO-LLINs
Footnotes
(1) Ifakara, Veeralin, Susceptible, An arabiensis. The population was resistant to deltamethrin and permethrin.
(2) Zeneti, Permanet 3.0, Susceptible
(3) Ifakara, Veeralin, Susceptible, An. arabiensis. The population was resistant to deltamethrin and permethrin.
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Analysis 2.11.   Comparison 2: Commercial pyrethroid-PBO nets versus commercial LLINs: hut







Heterogeneity: Tau² = 0.88; Chi² = 4.73, df = 1 (P = 0.03); I² = 79%






Heterogeneity: Tau² = 0.00; Chi² = 0.73, df = 1 (P = 0.39); I² = 0%
Test for overall effect: Z = 1.03 (P = 0.30)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.46; Chi² = 11.86, df = 3 (P = 0.008); I² = 75%
Test for overall effect: Z = 0.36 (P = 0.72)












































M-H, Random, 95% CI
1.11 [0.39 , 3.15]
0.25 [0.11 , 0.60]
0.52 [0.12 , 2.22]
1.73 [0.73 , 4.08]
1.12 [0.69 , 1.83]
1.25 [0.82 , 1.91]
0.87 [0.40 , 1.89]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours PBO-LLINs Favours LLINs
Footnotes
(1) Ifakara, Veeralin, Susceptible, An arabiensis. The population was resistant to deltamethrin and permethrin.
(2) Zeneti, Permanet 3.0, Susceptible
(3) Ifakara, Veeralin, Susceptible, An. arabiensis. The population was resistant to deltamethrin and permethrin.
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Analysis 2.12.   Comparison 2: Commercial pyrethroid-PBO nets versus commercial LLINs: hut









Heterogeneity: Tau² = 0.01; Chi² = 5.95, df = 3 (P = 0.11); I² = 50%






Heterogeneity: Tau² = 0.21; Chi² = 14.81, df = 1 (P = 0.0001); I² = 93%
Test for overall effect: Z = 0.49 (P = 0.63)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.07; Chi² = 34.38, df = 5 (P < 0.00001); I² = 85%
Test for overall effect: Z = 3.90 (P < 0.0001)






















































M-H, Random, 95% CI
1.76 [1.47 , 2.12]
1.57 [1.26 , 1.95]
2.41 [1.83 , 3.18]
1.76 [1.47 , 2.11]
1.81 [1.56 , 2.10]
1.64 [1.31 , 2.06]
0.84 [0.65 , 1.09]
1.18 [0.61 , 2.28]
1.59 [1.26 , 2.01]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours LLINs Favours PBO-LLINs
Footnotes
(1) Vallée du Kou, Permanet 3.0, High resistance
(2) Yaokoffikro, Permanet 3.0, High resistance
(3) Tengrela, Permanet 3.0, High resistance
(4) Vallee du Kou 5, Permanet 3.0, High resistance
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Analysis 2.13.   Comparison 2: Commercial pyrethroid-PBO nets versus commercial LLINs: hut trials,








Heterogeneity: Tau² = 0.03; Chi² = 4.29, df = 2 (P = 0.12); I² = 53%






Test for overall effect: Z = 2.63 (P = 0.009)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.05; Chi² = 10.34, df = 3 (P = 0.02); I² = 71%
Test for overall effect: Z = 4.04 (P < 0.0001)












































M-H, Random, 95% CI
0.59 [0.42 , 0.82]
0.60 [0.47 , 0.78]
0.38 [0.26 , 0.56]
0.53 [0.40 , 0.69]
0.76 [0.61 , 0.93]
0.76 [0.61 , 0.93]
0.58 [0.45 , 0.76]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours PBO-LLINs Favours LLINs
Footnotes
(1) Vallée du Kou, Permanet 3.0, High resistance
(2) Tengrela, Permanet 3.0, High resistance
(3) Vallee du Kou 5, Permanet 3.0, High resistance
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Analysis 2.14.   Comparison 2: Commercial pyrethroid-PBO nets versus commercial LLINs: hut








Heterogeneity: Tau² = 0.00; Chi² = 2.17, df = 2 (P = 0.34); I² = 8%






Test for overall effect: Z = 3.16 (P = 0.002)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 2.22, df = 3 (P = 0.53); I² = 0%
Test for overall effect: Z = 8.08 (P < 0.00001)












































M-H, Random, 95% CI
1.96 [1.49 , 2.56]
1.44 [1.05 , 1.97]
1.72 [1.41 , 2.09]
1.72 [1.48 , 1.99]
1.81 [1.25 , 2.61]
1.81 [1.25 , 2.61]
1.73 [1.51 , 1.97]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours LLINs Favours PBO-LLINs
Footnotes
(1) Malanaville, Olyset Plus, High resistance
(2) Tengrela, Olyset Plus, High resistance
(3) Vallee du Kou 5, Olyset Plus, High resistance
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Analysis 2.15.   Comparison 2: Commercial pyrethroid-PBO nets versus commercial LLINs: hut trials,








Heterogeneity: Tau² = 0.18; Chi² = 9.75, df = 2 (P = 0.008); I² = 79%






Test for overall effect: Z = 2.18 (P = 0.03)
Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.14; Chi² = 10.72, df = 3 (P = 0.01); I² = 72%
Test for overall effect: Z = 2.03 (P = 0.04)












































M-H, Random, 95% CI
0.92 [0.37 , 2.24]
0.87 [0.67 , 1.14]
0.43 [0.29 , 0.62]
0.67 [0.38 , 1.18]
0.50 [0.27 , 0.93]
0.50 [0.27 , 0.93]
0.63 [0.40 , 0.98]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours PBO-LLINs Favours LLINs
Footnotes
(1) Malanville, Olyset Plus, High resistance
(2) Tengrela, Olyset Plus, High resistance
(3) Vallee du Kou 5, Olyset Plus, High resistance
 
 
A D D I T I O N A L   T A B L E S
 
WHOPES Phase Definition
WHOPES Phase I. Laboratory
bioassays
Cone bioassays: these studies are conducted in the laboratory setting and use standard WHO pro-
tocols (WHO 2013, Section 2.2.1), when mosquitoes are exposed to a suitable LLIN (treated inter-
vention or untreated control) for three minutes using a standard plastic WHO cone. Following net
exposure, mosquitoes are transferred to a holding container and are maintained on a sugar solu-
tion diet while entomological outcomes (mosquitoes knocked down 1 hour post exposure, and
mosquito mortality 24 hours post exposure) are measured.
Tunnel tests: these studies are conducted in the laboratory setting and use standard WHO proto-
cols (WHO 2013, Section 2.2.2). Mosquitoes are released into a glass tunnel covered at each end
with untreated netting. The intervention or control LLIN net sample is placed one-third down the
length of the tunnel, and the net contains 9 holes that enable mosquitoes to pass through. A suit-
able bait is immobilized in the shorter section of the tunnel, where it is available for mosquito bit-
ing. Mosquitoes are released into the opposite end of the tunnel and must make contact with the
net and locate holes before they are able to feed on the bait. After 12 to 15 hours, mosquitoes are
removed from both sections of the tunnel, and entomological outcomes (the number of mosqui-
toes in each section, mortality, and blood-feeding inhibition at the end of the assay and 24 hours
post exposure) are recorded.
Table 1.   World Health Organization Pesticide Evaluation Scheme (WHOPES) classification 
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Wire-ball bioassays: these studies are conducted in the laboratory setting, where mosquitoes are
introduced into a wire-ball frame that has been covered with the intervention or control LLIN. Mos-
quitoes are exposed for 3 minutes, after which they are transferred to a holding container, and en-
tomological outcomes (mosquitoes knocked down 1 hour post exposure, and mosquito mortality
24 hours post exposure) are measured.
WHOPES Phase II. Experimen-
tal hut trials
WHOPES Phase II experimental hut trials are field trials conducted in Africa where wild mosquito
populations or local colonized populations are evaluated. Volunteers or livestock sleep in experi-
mental huts under a purposefully holed LLIN, with 1 person or animal per hut. Huts are designed to
resemble local housing based on a West or East African design (WHO 2013; Section 3.3.1-2). Howev-
er these trials have identical design features, such as eave gaps or entry slits to allow mosquitoes
to enter, and exit traps to capture exiting mosquitoes. LLINs and volunteers are randomly allocat-
ed to huts and are rotated in a Latin square to avoid bias, with huts cleaned between rotations to
avoid contamination. Several nets, including an untreated control net, can be tested at the same
time. Dead and live mosquitoes are collected each morning from inside the net, inside the hut, and
inside the exit traps. They are then scored as blood-fed or non-blood-fed, and as alive or dead, and
live mosquitoes are maintained for a further 24 hours to assess delayed mosquito mortality.
WHOPES Phase III. Village tri-
als
WHOPES Phase III village trials are conducted in Africa where wild mosquito populations are eval-
uated. Villages chosen to be included in the study are similar in terms of size, housing structure, lo-
cation, and data available on insecticide resistance status of local malaria vectors. Households are
assigned as conventional LLINs or PBO-LLINs. Randomization can be done at the household or vil-
lage level. Adult mosquitoes are collected from study houses, and mosquito density is measured.
An indication of malaria transmission is measured at the study sites by recording infections in mos-
quitoes, parasite prevalence, or malaria incidence.
Table 1.   World Health Organization Pesticide Evaluation Scheme (WHOPES) classification  (Continued)
LLIN: long-lasting insecticidal nets; PBO: piperonyl butoxide; WHOPES: World Health Organization Pesticide Evaluation Scheme.
 
 
Product name Product type Status of WHO recom-
mendation
DawaPlus 2.0 Deltamethrin coated on polyester Interim
DawaPlus 3.0 Combination of deltamethrin coated onto polyester (side panels) and
deltamethrin and PBO incorporated into polyester (roof)
Interim
DawaPlus 4.0 Deltamethrin and PBO incorporated into polyester Interim
Duranet Alpha-cypermethrin incorporated into polyethylene Full
Interceptor Alpha-cypermethrin coated on polyester Full
Interceptor G2 Alpha-cypermethrin and chlorfenapyr incorporated into polyester Interim
LifeNet Deltamethrin incorporated into polypropylene Interim
MAGNet Alpha-cypermethrin incorporated into polyethylene Full
MiraNet Alpha-cypermethrin incorporated into polyethylene Interim
Olyset Net Permethrin incorporated into polyethylene Full
Olyset Plus Permethrin (20 g/kg) and PBO (10 g/kg) incorporated into polyethylene Interim
Panda Net 2.0 Deltamethrin incorporated into polyethylene Interim
Table 2.   World Health Organization (WHO)-recommended long-lasting insecticidal nets (LLINs) 
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PermaNet 2.0 Deltamethrin coated on polyester Full
PermaNet 3.0 Combination of deltamethrin coated on polyester with strengthened border
(side panels) and deltamethrin and PBO incorporated into polyethylene (roof)
Interim
Royal Sentry Alpha-cypermethrin incorporated into polyethylene Full
SafeNet Alpha-cypermethrin coated on polyester Full
Veeralin Alpha-cypermethrin and PBO incorporated into polyethylene Interim
Yahe Deltamethrin coated on polyester Interim
Yorkool Deltamethrin coated on polyester Full
Table 2.   World Health Organization (WHO)-recommended long-lasting insecticidal nets (LLINs)  (Continued)




Alpha-cypermethrin SC 10% 20 to 40
Cyfluthrin EW 5% 50
Deltamethrin SC 1%
WT 25%
WT 25% + binderb
15 to 25
Etofenprox EW 10% 200
Lambda-cyhalothrin CS 2.5% 10 to 15
Permethrin EC 10% 200 to 500
Table 3.   World Health Organization (WHO)-recommended insecticide products for treatment of mosquito nets for
malaria vector control 







Suspected resistance Susceptible Unclassified
WHO mosquito mortalitya < 90% 90% to 97% 98% to 100% Unknown
CDC knock-downb < 90% 80% to 97% 98% to 100% Unknown
Table 4.   Definition of resistance level 
CDC: Centers for Disease Control and Prevention; WHO: World Health Organization.
aDefinition of resistance level based on mosquito mortality (%) aQer exposure to insecticide in a WHO diagnostic dose assay.
bDefinition of resistance level based on mosquito mortality (%) aQer exposure to insecticide in a CDC bottle bioassay using the methods,
diagnostic doses, and diagnostic times recommended by each test respectively.
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Outcome Low Moderate High Unclassified
Mosquito mortalitya 61% to 90% 31% to 60% < 30% Unknown
Table 5.   Stratification of resistance level 







Did the study test Anopheles gambiae complex or
Anopheles funestus group mosquitoes?
↓ — ↓ State mosquito
species
Were a minimum of 50 mosquitoes tested per study
arm?
↓ — ↓  
Intervention
Did the study include a long-lasting insecticidal net
(LLIN) or insecticide-treated net (ITN)?
↓ — ↓ State net LLIN or
ITN
Was the intervention net either of the following?
1. A piperonyl butoxide (PBO) LLIN that received a
minimum of interim World Health Organization
(WHO) approval.
↓ — ↓ State net type
Was the control net either of the following?
1. A pyrethroid LLIN of the same fabric impregnated
with the same insecticide and dose as the inter-
vention net.
2. A pyrethroid LLIN impregnated with the same in-
secticide at any dose.




Was the study one of the following?
1. Experimental hut study
2. Village trial
↓ — ↓ State study type
For experimental hut study and village trial. Was
the study conducted in Africa?
↓ — ↓ State country
Outcome
Did the study include at least 1 of the following out-
come measures?
1. Mortality
↓ — ↓  
Table 6.   Study inclusion screening form 
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2. Blood feeding
3. Sporozoite rate










Table 6.   Study inclusion screening form  (Continued)
ITN: insecticide-treated net; LLIN: long-lasting insecticidal net; PBO: piperonyl butoxide; WHO: World Health Organization.
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Bayili 2017 Vallée du Kou DawaPlus 2.0 No 1548 1848 16.23 16.23
Bayili 2017 Vallée du Kou DawaPlus 2.0 Yes 2155 1848 0 -16.61
Bayili 2017 Vallée du Kou DawaPlus 3.0 No 1365 1848 26.13 26.14
Bayili 2017 Vallée du Kou DawaPlus 3.0 Yes 1981 1848 0 -7.20
Bayili 2017 Vallée du Kou DawaPlus 4.0 No 846 1848 54.22 54.22
Bayili 2017 Vallée du Kou DawaPlus 4.0 Yes 1646 1848 10.93 10.93
Corbel 2010 Malanville Permanet 2.0 Yes 195 285 31.58 31.58
Corbel 2010 Malanville Permanet 3.0 Yes 210 285 26.32 26.32
Corbel 2010 Malanville Permanet 2.0 No 243 285 14.74 14.74
Corbel 2010 Malanville Permanet 3.0 No 214 285 24.91 24.91
Corbel 2010 Pitoa Permanet 2.0 Yes 310 401 22.69 22.69
Corbel 2010 Pitoa Permanet 3.0 Yes 163 401 59.35 59.35
Corbel 2010 Pitoa Permanet 2.0 No 105 401 73.82 73.82
Corbel 2010 Pitoa Permanet 3.0 No 146 401 63.59 63.59
Corbel 2010 Vallée du Kou Permanet 2.0 Yes 788 908 13.22 13.22
Corbel 2010 Vallée du Kou Permanet 3.0 Yes 724 908 20.26 20.26
Corbel 2010 Vallée du Kou Permanet 2.0 No 329 908 63.77 63.77
Corbel 2010 Vallée du Kou Permanet 3.0 No 463 908 49.01 49.01
Koudou 2011 Yaokoffikro Permanet 3.0 No 303 796 62.1 61.93






























































































































































































Koudou 2011 Yaokoffikro Permanet 2.0 No 317 796 60.4 60.18
Koudou 2011 Yaokoffikro Permanet 3.0 Yes 313 796 60.1 60.68
Koudou 2011 Yaokoffikro Permanet 2.0 Yes 281 796 64.4 64.70
Menze 2020 Mibellon PermaNet 2.0 No 237 390 39.2 39.2
Menze 2020 Mibellon PermaNet 3.0 No 153 390 60.8 60.8
Menze 2020 Mibellon Olyset Net No 176 390 54.9 54.9
Menze 2020 Mibellon Olyset Plus No 199 390 49 49
Moore 2016 Ifakara Veeralin LN No 722 810 11 10.86
Moore 2016 Ifakara Veeralin LN Yes 727 810 10 10.25
Moore 2016 Ifakara MAGNet LN No 1070 810 0 -32.10
Moore 2016 Ifakara MAGNet LN Yes 773 810 5 4.57
Moore 2016 Ifakara Veeralin LN No 89 170 48 47.65
Moore 2016 Ifakara Veeralin LN Yes 85 170 50 50.00
Moore 2016 Ifakara MAGNet LN No 114 170 33 32.94
Moore 2016 Ifakara MAGNet LN Yes 103 170 39 39.41
N'Guessan 2010 Akron Permanet 3.0 No 128 185 31 30.81
N'Guessan 2010 Akron Permanet 3.0 Yes 155 185 NR 16.22
N'Guessan 2010 Akron Permanet 2.0 No 114 185 38 38.38
N'Guessan 2010 Akron Permanet 2.0 Yes 174 185 NR 5.95
Pennetier 2013 Malanville Olyset Plus No 67 69 NR 2.90
Pennetier 2013 Malanville Olyset Plus Yes 101 69 NR -46.38






























































































































































































Pennetier 2013 Malanville Olyset Net No 96 69 NR -39.13
Pennetier 2013 Malanville Olyset Net Yes 124 69 NR -79.71
Toé 2018 Tengrela Olyset Net No 923 480 -92.29 -92.29
Toé 2018 Tengrela Olyset Plus No 695 480 -44.79 -44.79
Toé 2018 Tengrela Permanet 2.0 No 858 480 -78.75 -78.75
Toé 2018 Tengrela Permanet 3.0 No 794 480 -65.42 -65.42
Toé 2018 VK5 Olyset Net No 1458 1095 -33.15 -33.15
Toé 2018 VK5 Olyset Plus No 1278 1095 -16.71 -16.71
Toé 2018 VK5 Permanet 2.0 No 1075 1095 1.83 1.83
Toé 2018 VK5 Permanet 3.0 No 657 1095 40 40.00
Tungu 2010 Zeneti PermaNet 3.0 No 425 723 41 41.22
Tungu 2010 Zeneti PermaNet 2.0 No 574 723 21 20.61
Tungu 2010 Zeneti PermaNet 3.0 Yes 558 723 23 22.82
Tungu 2010 Zeneti PermaNet 2.0 Yes 586 723 19 18.95
Table 7.   Experimental hut trials: deterrence data  (Continued)
ITN: insecticide-treated net; LLIN: long-lasting insecticidal net; NR: not reported; PBO: piperonyl butoxide; UTN: untreated net; WHO: World Health Organization.
 
 









Awolola 2014 Untreated An gambiae s.l. Mean number caught per house WT, IRC 16.2 17.1 -5.56
Awolola 2014 PermaNet 2.0 An gambiae s.l. Mean number caught per house WT, IRC 21.3 7.2 66.20
Awolola 2014 PermaNet 3.0 An gambiae s.l. Mean number caught per house WT, IRC 20.1 1.4 93.03






























































































































































































Cisse 2017 PermaNet 2.0 An gambiae s.l. Resting density per room per day IRC - 1.92 -
Cisse 2017 PermaNet 3.0 An gambiae s.l. Resting density per room per day IRC - 3.05 -
Cisse 2017 Olyset An gambiae s.l. Resting density per room per day IRC - 3.21 -
Cisse 2017 Olyset Plus An gambiae s.l. Resting density per room per day IRC - 3.7 -
Mzilahowa 2014 Olyset An gambiae Mean number caught per catch PSC - 0.10 -
Mzilahowa 2014 Olset Plus An gambiae Mean number caught per catch PSC - 0.12 -
Mzilahowa 2014 PermaNet 2.0 An gambiae Mean number caught per catch PSC - 0.13 -
Mzilahowa 2014 PermaNet 3.0 An gambiae Mean number caught per catch PSC - 0.09 -
Mzilahowa 2014 Olyset An funestus Mean number caught per catch PSC - 0.08 -
Mzilahowa 2014 Olyset Plus An funestus Mean number caught per catch PSC - 0.16 -
Mzilahowa 2014 PermaNet 2.0 An funestus Mean number caught per catch PSC - 0.27 -
Mzilahowa 2014 PermaNet 3.0 An funestus Mean number caught per catch PSC - 0.13 -
Mzilahowa 2014 Olyset An gambiae Mean number caught per catch LT - 1.23 -
Mzilahowa 2014 Olset Plus An gambiae Mean number caught per catch LT - 0.27 -
Mzilahowa 2014 PermaNet 2.0 An gambiae Mean number caught per catch LT - 0.96 -
Mzilahowa 2014 PermaNet 3.0 An gambiae Mean number caught per catch LT - 1.44 -
Mzilahowa 2014 Olyset An funestus Mean number caught per catch LT - 2.02 -
Mzilahowa 2014 Olset Plus An funestus Mean number caught per catch LT - 2.1 -
Mzilahowa 2014 PermaNet 2.0 An funestus Mean number caught per catch LT - 5.76 -
Mzilahowa 2014 PermaNet 3.0 An funestus Mean number caught per catch LT - 3.76 -
Protopopoff 2018 Olyset (2015) Anopheles
species
Mean number caught per house per
night
LT - 2.61 -






























































































































































































Protopopoff 2018 Olyset Plus (2015) Anopheles
species
Mean number caught per house per
night
LT - 1.85 -
Protopopoff 2018 Olyset (2016) Anopheles
species
Mean number caught per house per
night
LT - 3.60 -
Protopopoff 2018 Olyset Plus (2016) Anopheles
species
Mean number caught per house per
night
LT - 2.68 -
Staedke 2020 Permanet 2.0 (6
months)
An gambiae s.l. Mean density per house IRC 0.3 0.67  
Staedke 2020 Permanet 3.0 (6
months)
An gambiae s.l. Mean density per house IRC 0.8 0.17 78.75
Staedke 2020 Olyset (6 months) An gambiae s.l. Mean density per house IRC 0.3 0.81  
Staedke 2020 Olyset Plus (6
months)
An gambiae s.l. Mean density per house IRC 0.1 0.16  
Staedke 2020 Permanet 2.0 (12
months)
An gambiae s.l. Mean density per house IRC 0.3 1.35  
Staedke 2020 Permanet 3.0 (12
months)
An gambiae s.l. Mean density per house IRC 0.8 0.52 35
Staedke 2020 Olyset (12
months)
An gambiae s.l. Mean density per house IRC 0.3 1.1  
Staedke 2020 Olyset Plus (12
months)
An gambiae s.l. Mean density per house IRC 0.1 0.23  
Staedke 2020 Permanet 2.0 (18
months)
An gambiae s.l. Mean density per house IRC 0.3 1.65  
Staedke 2020 Permanet 3.0 (18
months)
An gambiae s.l. Mean density per house IRC 0.8 1.57  
Staedke 2020 Olyset (18
months)
An gambiae s.l. Mean density per house IRC 0.3 0.66  
Staedke 2020 Olyset Plus (18
months)
An gambiae s.l. Mean density per house IRC 0.1 0.19  






























































































































































































Stiles-Ocran 2013 No intervention An gambiae s.s. Mean number caught per village IRC 230 79 65.65
Stiles-Ocran 2013 Permanet 2.0 An gambiae s.s. Mean number caught per village IRC 39 36 7.69
Stiles-Ocran 2013 Permanet 2.0 An gambiae s.s. Mean number caught per village IRC 82 45 45.12
Stiles-Ocran 2013 Permanet 3.0 An gambiae s.s. Mean number caught per village IRC 77 12 84.42
Stiles-Ocran 2013 Permanet 3.0 An gambiae s.s. Mean number caught per village IRC 178 15 91.57

























Table 8.   Village trials: mosquito density data  (Continued)




































































Cochrane Database of Systematic Reviews
 
A P P E N D I C E S




#2 MeSH descriptor: [Piperonyl Butoxide] explode all trees
#3 #1 or #2
#4 Net* or bednet* or hammock* or curtain* or ITN* or LLIN* or "Insecticide-Treated Bednet*" or "Insecticide-Treated net*"
#5 Olyset* or PermaNet* or Veeralin
#6 DawaPlus* or Tsara* or Duranet*
#7 MeSH descriptor: [Insecticide-Treated Bednets] explode all trees
#8 #4 or #5 or #6 or #7




#1 Search "Piperonyl Butoxide"[Mesh]
#2 Search piperonyl butoxide or PBO Field: Title/Abstract
#3 Search ("Piperonyl Butoxide"[MESH]) OR #2
#4 Search Net* OR bednet* OR curtain* OR ITN* OR LLIN* or "Insecticide-Treated Bednet*" or "Insecti-
cide-Treated net*" Field: Title/Abstract
#5 Search "Olyset* or Permanet* or Veeralin Field: Title/Abstract
#6 Search DawaPlus* or Tsara* or Duranet* Field: Title/Abstract
#7 Search "Insecticide-Treated Bednets" [MESH]
#8 Search (((#4) OR #) OR #6) OR #7






3 1 or 2
4 PBO.tw.
5 3 or 4
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6 (Net* or bednet* or hammock* or curtain* or ITN* or LLIN* or "Insecticide-Treated Bednet*" or "Insecticide-Treated net*").mp.
7 (Olyset* or Permanet* or Veeralin).mp.
8 (DawaPlus* or Tsara* or Duranet*).mp.
9 insecticide treated net/
10 6 or 7 or 98 or 9
11 5 and 10
Web of ScienceTM Core Collection
 
Set  
# 5 #3 AND #4
Indexes=SCI-EXPANDED, SSCI, CPCI-S, CPCI-SSH Timespan=All years
# 4 #1 OR #2
Indexes=SCI-EXPANDED, SSCI, CPCI-S, CPCI-SSH Timespan=All years
# 3 TOPIC:
(Net* OR bednet* OR ITN* OR LLIN* or “Insecticide-Treated Bednet*” or “Insecticide-Treated net*”)
OR TOPIC: (Olyset* or PermaNet* or Veeralin) OR TOPIC: (DawaPlus*or Tsara* or Duranet*)
Indexes=SCI-EXPANDED, SSCI, CPCI-S, CPCI-SSH Timespan=All years
# 2 TOPIC: (PBO) NOT TOPIC: (placebo)
Indexes=SCI-EXPANDED, SSCI, CPCI-S, CPCI-SSH Timespan=All years
# 1 TOPIC: ("Piperonyl Butoxide")






# 3 #2 AND #1
Indexes=CAB Abstracts Timespan=All years
# 2 TOPIC: (Net* OR bednet* OR hammock* OR curtain* OR ITN* OR LLIN* or “Insecticide-Treated Bed-
net*” or “Insecticide-Treated net*”) OR TOPIC: (Olyset* or PermaNet* or Veeralin)
Indexes=CAB Abstracts Timespan=All years
# 1 TOPIC: (PBO or "Piperonyl Butoxide")
Indexes=CAB Abstracts Timespan=All years
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Appendix 2. Study characteristics extraction form
Table 2.1 Trial characteristics of the included experimental hut trials
Piperonyl butoxide (PBO) combined with pyrethroids in insecticide-treated nets to prevent malaria in Africa (Review)
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BF; blood feeding; D: deterrence; E: exophily; M: mortality.
Table 2.2 Trial characteristics of the included village trials
Piperonyl butoxide (PBO) combined with pyrethroids in insecticide-treated nets to prevent malaria in Africa (Review)
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BF: blood feeding; CMC: clinical malaria confirmation; M: mortality; MD: mosquito density; PP: parasite presence; PR: parity rate; SR:
sporozoite rate.
Appendix 3. Data extraction form
Table 3.1 Data extracted from experimental hut trials
Piperonyl butoxide (PBO) combined with pyrethroids in insecticide-treated nets to prevent malaria in Africa (Review)
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BF: blood feeding; BFI: blood feeding inhibition; N: number of people.
Table 3.2 Data extracted from village trials
Piperonyl butoxide (PBO) combined with pyrethroids in insecticide-treated nets to prevent malaria in Africa (Review)


























































































































































































































































Cochrane Database of Systematic Reviews
BF: blood feeding; CMC: clinical malaria confirmation; N: number of people; PP: parasite prevalence.
Appendix 4. ‘Risk of bias' assessment form
Table 4.2 ‘Risk of bias' assessment for experimental hut trials
Piperonyl butoxide (PBO) combined with pyrethroids in insecticide-treated nets to prevent malaria in Africa (Review)
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LLIN: long-lasting insecticidal nets; PBO: piperonyl butoxide.
Table 4.3 ‘Risk of bias' assessment for village trials
Piperonyl butoxide (PBO) combined with pyrethroids in insecticide-treated nets to prevent malaria in Africa (Review)





































































































































Trial ID Trial name Comparability of mosquitoes in
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LLIN: long-lasting insecticidal nets; PBO: piperonyl butoxide.
Appendix 5. ‘Risk of bias' assessment: experimental hut trials
 





Huts accessible to the same
mosquito population
No or unclear information report-
ed
Huts not accessible to the same mosquito
population
Collectors blinded Outcomes assessed blinded No or unclear information report-
ed
If outcomes assessed were not
blinded, but this is unlikely to in-
fluence the results, we will judge
this to be low risk
Outcomes assessed not blinded, and this
is likely to influence the results
If outcomes assessed were not blinded,
but this is unlikely to influence the re-
sults, we will judge this to be low risk
Sleepers blinded Outcomes assessed blinded No or unclear information report-
ed
If outcomes assessed were not
blinded, but this is unlikely to in-
fluence the results, we will judge
this to be low risk
Outcomes assessed not blinded, and this
is likely to influence the results
If outcomes assessed were not blinded,
but this is unlikely to influence the re-
sults, we will judge this to be low risk
Sleeper bias Sleepers were rotated be-
tween huts according to a
Latin square design
No or unclear information report-
ed





ized; however equal attrac-
tiveness demonstrated
No or unclear information report-
ed
Treatments not randomized, and equal
attractiveness not demonstrated
Treatment rotation Treatments rotated through
huts according to a Latin
square design





Huts of West or East African
design
No or unclear information report-
ed
Huts of non-standardized design
Cleaning Huts cleaned between
treatments
No or unclear information report-
ed




No or low missing data; rea-
son for missing data is un-
likely to be related to the
true outcome
No or unclear information report-
ed
High missing data; reason for missing da-
ta is likely to be related to the true out-
come
Raw data reported Raw data reported No or unclear information report-
ed
Raw data not reported
Conflicting inter-
ests
No conflict of interest stat-
ed
No or unclear information report-
ed
Conflict of interest stated
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Appendix 6. ‘Risk of bias' assessment: village trials
 
'Risk of bias' com-
ponent
Low Unclear High
Recruitment bias No participants recruit-
ed after clusters ran-
domized
No or unclear information reported
Recruitment bias not applicable to trial de-
sign, as it is related to human participants






No or unclear information reported Mosquito populations comparable
Collectors blinded Outcomes assessed
blinded
No or unclear information reported
Outcomes assessed not blinded, but this is
unlikely to influence the results
Outcomes assessed not blinded,
and this is likely to influence the
results
Household blinded Outcomes assessed
blinded
No or unclear information reported
If outcomes assessed were not blinded, but
this is unlikely to influence the results, we
will judge this to be low risk
Outcomes assessed not blinded,
and this is likely to influence the
results
If outcomes assessed were not
blinded, but this is unlikely to in-
fluence the results, we will judge











No or unclear information reported
Allocation concealment procedures were
not adhered to; however this is unlikely to
affect the results
Allocation procedures were not ad-





No or low missing data;
reason for missing data
is unlikely to be related
to the true outcome
No or unclear information reported High missing data; reason for miss-
ing data is likely to be related to
the true outcome
Raw data reported Raw data reported No or unclear information reported Raw data not reported




No or unclear information as to whether
clusters were lost from trial
At least 1 cluster lost from trial
Selective reporting No selective reporting;
all measured outcomes
reported in results
No or unclear information on whether all
measured outcomes were reported in re-
sults
Selective reporting; not all mea-





Clustering was taken in-
to account and statisti-
cal methods adjusted
for clustering
No or unclear information as to whether
clustering was taken into account for statis-
tical methods
Trial did not take clustering into
account for statistical methods
Conflicting inter-
ests
No conflict of interest
stated
No or unclear information reported Conflict of interest stated
 
Piperonyl butoxide (PBO) combined with pyrethroids in insecticide-treated nets to prevent malaria in Africa (Review)










Cochrane Database of Systematic Reviews
 
Appendix 7. Prespecified changes for review update 2021
 
Protocol section Protocol changes
Background and research
question
We will update any references and background information
Inclusion criteria We propose to remove objective 1 (evaluate whether adding PBO to pyrethroid LLINs increases
the epidemiological and entomological effectiveness of the nets’ and focus instead on comparing
pyrethroid-PBO nets with their non-PBO equivalent (objective 2).  As a result, laboratory studies
will be excluded. We make this decision as we only identified two studies meeting the inclusion cri-
teria for objective 1 in Gleave 2018, both of which were laboratory assays;  results from these can-
not readily be translated into public health outcomes.
Methods We will subgroup our analysis on epidemiological data by follow-up time.
We will update the search strategy terms as one brand of bednet has changed name, and we will
perform a new search to identify all possible trials.
 
 
This table was approved by the CIDG editorial team on 26 Oct 2020.
W H A T ' S   N E W
 
Date Event Description
14 May 2021 New search has been performed The prespecified changes to the protocol (before the review up-
date commenced) are given in Appendix 7. We excluded studies
using only laboratory assays from this review update due to the
challenges in extrapolating public health value from laboratory
bioassays alone. We amended the search strategy including dif-
ferent search terms due to a bed net brand name change. A new
search was undertaken to capture all relevant trials for this up-
date. 
24 March 2021 New citation required and conclusions
have changed
This is an update of the first Cochrane Review of pyrethroid-PBO
nets (Gleave 2018). The date of search is 25 September 2020.
 
H I S T O R Y
Protocol first published: Issue 8, 2017
Review first published: Issue 11, 2018
 
Date Event Description
6 June 2019 Amended Abstract amended. Authors' conclusions section: changed from
"reduce mosquito mortality and blood feeding rates" to "in-
crease mosquito mortality and reduce blood feeding rates"
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